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SUMMARY 
 The lipoxin A4 receptor (ALXR) is expressed in almost all leukocytes and plays an 
important role in host defense and inflammation such as rheumatoid arthritis and asthma. The 
receptor binds structurally diverse agonistic ligands, including peptides and lipid mediators, which 
mainly regulate chemotaxis and activation of polymorphonuclear neutrophils (PMN) and 
monocytes that enter the inflamed tissue. The regulation of ALXR is poorly described but a few 
regulators, involved in inflammation, have been identified to upregulate the expression of ALXR. 
For instance ALXR is regulated in enterocytes by cytokines such as interleukin-6 (IL-6) interleukin-
13 (IL-13) and interleukin-4 (IL-4). However, little is known about its own transcriptional and 
translational regulation in myeloid cells such as monocytes and macrophages. In this thesis I aim at 
better understanding the transcriptional regulation of the ALXR in macrophages to delineate its role 
during inflammation.  
I identified two promoter regions separated by 224 bps which drive the expression of the 
ALXR in macrophages. Both promoter regions increased transcription in a reporter assay and the 
basal transcription factors, OCT1 and SP1, were shown to bind the first and the second promoter, 
respectively, and to transactivate transcription. To investigate the ALXR mRNA expression in 
monocytes and macrophages, I measured basal expression of the ALXR mRNA during 
differentiation of monocytes to macrophages and stimulated mRNA expression in macrophages. 
While monocytes expressed high levels of ALXR mRNA, differentiation into macrophages 
abrogated ALXR expression. Stimulation of macrophages with a set of cytokines revealed that only 
IFNγ increased ALXR expression to levels similar to the ones detected in monocytes. This 
upregulation by IFNγ is in part mediated by IRF1 interacting with an IRSE transcription factor 
binding site located in the first promoter region of ALXR.  
These data support that the ALXR plays a role in the chemotaxis of monocytes, which 
results from a gradient of pro-inflammatory or anti-inflammatory ligands. Depending on the ligand 
and the environment of the invaded tissue, the monocyte may then differentiate into either an M1 or 
a M2 macrophage. Since IFNγ is known to induce the differentiation of macrophages into pro-
inflammatory M1 type macrophages, my data suggest that in the early phase of inflammation only 
M1 macrophages could further be triggered by the pro-inflammatory ligands of ALXR to generate 
inflammatory regulators and to recruit PMN and monocytes that recognize and kill pathogen. On 
the other hand, when anti-inflammatory lipid ligands occur at the site of inflammation, these M1 
macrophages may re-differentiate into M2 macrophages, and play a role in restoring tissue 
homeostasis. 
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ZUSAMMENFASSUNG 
Der Lipoxin A4 Rezeptor (ALXR) wird von nahezu allen Leukozyten exprimiert und erfüllt 
eine wichtige Funktion in der Wirtsabwehr und in entzündlichen Erkrankungen wie rheumatoide 
Arthritis und Asthma. Der Rezeptor bindet strukturell unterschiedliche agonistische Liganden. Dazu 
gehören Peptide und Lipidmediatoren, welche vor allem die Chemotaxis und die Aktivierung von 
polymorphkernigen neutrophilen Granulozyten (PMN) und Monozyten regulieren, die in 
entzündetes Gewebe einwandern. Die Regulierung von ALXR ist kaum beschrieben. Nur, einzelne 
an Entzündungen beteiligte Regulatoren die die Expression von ALXR erhöhen, wurden 
identifiziert. In Enterozyten wird ALXR beispielsweise von Zytokinen wie Interleukin-6 (IL-6), 
Interleukin-13 (IL-13) und Interleukin-4 (IL-4) reguliert. Jedoch ist wenig über seine 
transkriptionnelle und translationelle Regulierung in myeloiden Zellen wie Monozyten und 
Makrophagen bekannt. Das Ziel meiner Arbeit ist, ein besseres Verständnis der transkriptionalen 
Regulierung des ALXRs in Makrophagen zu erhalten, um dessen Funktion bei einer Entzündung zu 
verstehen. 
Ich habe zwei Promoterregionen, getrennt durch 224 Basenpaare, identifiziert, welche die 
Expression von ALXR in Makrophagen vermitteln. Beide Promoterregionen erhöhten die 
Transkription in einem Reporter-Assay, und es konnte gezeigt werden, dass die basalen 
Transkriptionsfaktoren OCT1 und SP1 an den ersten beziehungsweise den zweiten Promoter binden 
und die Transkription aktivieren. Um die Expression des ALXR in Monozyten und Makrophagen 
zu untersuchen, habe ich die basale Expression der ALXR-mRNA während der Differenzierung der 
Monozyten zu Makrophagen und die mRNA-Expression in stimulierten Makrophagen gemessen. 
Während Monozyten ALXR-mRNA in hoher Konzentration exprimierten, führte die 
Differenzierung zu Makrophagen zur Einstellung der ALXR-Expression. Stimulierung von 
Makrophagen mit verschiedenen Zytokinen zeigte, dass lediglich IFNγ die ALXR-Expression auf 
Konzentrationen ähnlich der in Monozyten gemessenen erhöhte. Diese Hochregulierung durch 
IFNγ wird zum Teil durch die Interaktion von IRF1 mit einer Bindungsstelle für den 
Transkriptionsfaktor IRSE vermittelt, welche sich in der ersten Promoterregion für ALXR befindet. 
Diese Daten bestätigen einen Einfluss von ALXR auf die Chemotaxis von Monozyten, die auf 
einen Gradienten von pro- oder anti-inflammatorischer Liganden zurückzuführen ist. Die Monozyte 
könnte abhängig vom Liganden und vom Milieu des invadierten Gewebes entweder in eine M1- 
oder eine M2-Makrophage differenzieren. Da IFNγ dafür bekannt ist, die Differenzierung von 
Makrophagen zu pro-inflammatorischen Makrophagen vom Typ M1 zu induzieren, legen meine 
Ergebnisse nahe, dass in der frühen Phase der Entzündung nur M1-Makrophagen durch die pro-
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inflammatorischen Liganden von ALXR aktiviert werden können. Diese aktivierten M1-
Makrophagen könnten inflammatorische Regulatoren bilden und PMN und Monozyten rekrutieren, 
welche Pathogene erkennen und vernichten. Wirken jedoch anti-inflammatorische Lipidliganden an 
der Entzündungsstelle, könnten diese M1-Makrophagen zu M2-Makrophagen redifferenzieren und 
mithelfen, die Homöostase des Gewebes wiederherzustellen. 
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1 INTRODUCTION 
 
1.1 Inflammation and innate immune response 
 
The definition of inflammation is the overall phenomenon of the organism defence against 
traumatism, irritation and infection characterized by dolor, calor (heat), tumor (swelling) and rubor 
(redness). It is an attempt to protect the organism in removing the danger and in restoring tissue 
physiological function through the healing process. Inflammation is generally considered beneficial 
and has evolved as an adaptive response for restoring homeostasis [1]. In the absence of 
inflammation, tissue would be gradually damaged, which could lead to death of the organism. 
Acute inflammation lasts from a few hours to a few days and requires the activation of the innate 
and later the adaptive immune response. It consists of increases in the blood flow, activation of the 
plasma cascade and augmentation of permeability across blood capillaries. It is characterized by a 
quick migration of white blood cells, named leukocytes, from the blood to the injured sites where 
they elicit an inflammatory response. However when dysregulated inflammation becomes a 
pathological state lasting months to years, it is described as chronic inflammation. Much less is 
known about the causes and mechanisms of chronic inflammation, which occurs in several diseases 
such as asthma, inflammatory bowel disease, rheumatoid arthritis and atherosclerosis.  
 
1.1.1 Danger signals and recognition  
 
The first line of the host defence in inflammation is the epithelial barrier that stops any 
pathogen to enter the tissue. If this is not avoided, innate immunity responds to the intruder via 
proteins in the plasma cascade and phagocytic cells like macrophages and dendritic cells which 
recognize special features of the pathogen, the danger-associated molecular patterns (DAMPs) [2]. 
DAMPs include Gram negative and Gram positive bacteria, LPS, lipopeptides, lipoteichoic acid, 
double stranded DNA and single stranded RNA, allergens, toxic compounds, cell death products, 
heat shock proteins, adenosine, urate crystals and fibrinogen [3]. DAMPs are recognized by the host 
cells through specific recognition receptors, the pattern recognition receptors (PRRs). They have 
several different functions. The phagocytic receptors, such as macrophage mannose receptors and 
scavenger receptors (SRs), stimulate ingestion of the pathogen they recognize. The nod-like 
receptors (NLRs) recognize bacteria products and the chemotatic receptors that recognize N-
formylated peptides from bacteria and guide polymorphonulcear neutrophils (PMNs) to the sites of 
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infection. More specific receptors are the mannose binding lectin (MBLs) soluble receptors, which 
activate the complement system consisting of several soluble proteins interacting with each others 
to induce the recruitment of inflammatory cells which leads to phagocytosis and lysis of the 
pathogen [4]. Other PRRs are the toll like receptors (TLRs) which trigger gene expression in 
response to intruders and mediate their actions through signal transduction pathways such as 
mitogen activated protein kinase (MAPK) and transcriptional elements like nuclear factor kappa 
light chain enhancer of activated B cells (NF-κB), interferon regulatory factor 3 (IRF3) or activating 
protein (AP-1) [5]. TLRs interact also with co-stimulatory molecules such as CD14 and participate 
in the induction of the adaptive immune response when the innate immunity is overwhelmed. 
 
1.1.2 Pro-inflammatory messengers and cell chemotaxis 
 
PRRs elicit inflammatory response in cells of the immune system by producing mediators 
and signalling molecules such as growth factors, chemokines and cytokines. Cytokines induce 
expression of acute phase proteins such as C-reactive protein (CRP) from the liver that will help to 
eliminate the pathogen by activating the complement system. Increasing gradients of pro-
inflammatory cytokines such as interleukin 1β (IL-1β), interleukin 12 (IL-12), interleukin 8 (Il-8) 
interleukin 6 (IL-6) and tumor-necrosis factor α (TNFα) attract platelets and leukocytes like PMNs, 
basophils, eosinophils and mast cells to the site of inflammation [6-8]. They are supported by 
several cysteine-cysteine type chemokines; the CCL2 (also monocyte chemotactic protein MCP-1), 
CCL5 (also RANTES), CXCL-12 and CX3CL1 to recruit leukocytes [9, 10]. At the same time, 
endothelial cells lining the local blood vessel start to express adhesion proteins such as integrins, 
selectins E and P and members of the intercellular adhesion molecules (ICAM-1 and -2), vascular 
cell adhesion molecules (VCAM1) and platelet-endothelial cell adhesion molecule (PECAM-1) that 
will capture the oncoming leukocytes. The circulating leukocytes are slowed down toward the site 
of inflammation and begin to roll along the inner surface of the blood vessel making bonds with the 
selectins. The chemokines and integrins then induce firm adhesion and immobilisation of the 
leukocytes which release proteases to degrade the basement membranes. Leukocytes transmigrate 
with the help of PECAM- 1 through gaps between the endothelial cells and recognize the intruder 
through their cell surface receptors that can discriminate between host and pathogen cell surface 
particles to mediate correct immune response.  
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1.1.3 Inflammatory response 
 
Recognition of the intruder by the host cells leads to the phagocytosis of the pathogen 
followed by its internalization into the phagosome or endocytic vacuole via cytoskeletal 
remodelling and organization of actin filament involving Rho, Rac and Cdc42 signaling pathway 
[11]. Normally these vesicles become acidified to kill the pathogen. Also they can fuse with 
lysosomes that contain enzymes, peptides and proteins which mediate inflammatory response. 
PMNs, mast cells, natural killer (NK) cells, eosinophils and basophils are particularly interesting in 
terms of host defence because they contain granules whose specific contents are released in the 
micro-environment to attack the pathogen. Granules contain myeloperoxidase (MPO) and the 
membrane-associated NADPH oxidases which contribute to the formation of reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) that are generated via a so called respiratory 
burst process as large volumes of oxygen are consumed at that time. Among them are superoxide 
(O2-) hydrogen peroxide (H2O2), hypochlorous acid (HOCl) singlet oxygen (O2), hydroxyl radical 
(OH), nitryl chloride (NO2Cl), chloramines (RNHCl), radical product (AH) and compound III 
(MPO3+O2-). Together with MPO, they function as potent antimicrobial agents and serve as 
modulators of proteins, lipid kinases and phosphatases, transcription factors, including NF-κB, 
membrane receptors and ion channels functions [12]. However these responses can become 
deleterious and lead to cell deaths, tissue degradations and organ dysfunctions. Indeed NO 
production from the inducible nitric oxide synthase (iNOS) is harmful because it increases vascular 
permeability and has potent oxidative properties [13]. A derivative of NO, the peroxynitrite 
(ONOO-), can react with lipids to initiate lipid peroxidation resulting in cell and DNA damage 
causing the recruitment and activation of the poly ADP-ribose polymerase. This will decrease 
NAD+ stores and alter the redox state of the cells. Additionally PMN-released elastases disrupt 
tight junctions and contribute to proteolytic damage of the tissue. Thus an extended inflammatory 
response is detrimental for the tissue and leads to adverse physiological consequence such as 
chronic inflammation. 
 
1.1.4 Resolution of inflammation 
 
Prolonged inflammation can cease to be beneficial and therefore has to be stopped. Thus once 
the pathogen is killed, resolution mechanisms start as an active process and stop the signals leading 
to the synthesis of the pro-inflammatory mediators such as chemokines, cytokines and cell adhesion 
molecules. For instance fibroblasts participate in the withdrawal of survival signals and normalize 
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chemokine gradients that will prevent further recruitment of leukocytes. Furthermore, other end 
signals, such as the vasoactive NO, released by the endothelial nitric oxidase synthase (eNOS) or 
the anti-inflammatory cytokines IL-10 and TGFβ reduce leukocytes adhesion and infiltration [14]. 
Resolution of inflammation can occur only if granulocytes such as PMNs and mononuclear cells 
like macrophages and lymphocytes return to normal pre-inflammation numbers and phenotypes 
[15]. Thus cells need to be removed from the tissue through either systemic re-circulation or local 
cell death. The stop signals mentioned above also support the apoptosis of leukocytes which are 
taken up by nonphlogistic monocytes-derived macrophages. Moreover, the anti-inflammatory 
glucocorticoids and annexins stimulate macrophages to take up apoptotic PMN and other 
leukocytes from the inflamed tissue in a pro-resolving fashion [16-18]. Once phagocytosis is 
complete, macrophages exit the inflamed tissue by lymphatic drainage with evidence that a small 
portion may die locally by apoptosis. Each of the steps leading to the return of normal tissue 
homeostasis are coordinated and are under the thight control of pro-resolving factors such as the 
lipid mediators discussed in the next chapter [19]. However, defect in these endogenous anti-
inflammatory pathways may predispose the host to chronic inflammatory disease. Successful 
resolution will therefore limit excessive tissue damage and organ dysfunctions and give little 
opportunity for the development of chronic inflammation [20]. 
 
1.2  Lipid mediators 
 
1.2.1 Lipid mediator in inflammation 
 
The lipids mediators are chemical messengers that have hormone-like effects mediated by 
specialized receptors during the course of inflammation and are generally derived from essential 
fatty acids (EFA) that includes C20 arachidonic acid (AA), C20 eicosapentanoic acid (EPA) and the 
C22 docosahexanoic acid (DHA).  
 
DHA and EPA are part of the omega-3 fatty acids which have in common a final carbon–
carbon double bond in the n−3 position from the terminal methyl end of the carbon chain. In the 
early 80s they gained the interest of the scientific world because of their heart-health benefit. In 
1984 researchers associated seafood diet with reduced triglyceride levels and blood pressure in the 
Eskimos population [21]. Furthermore, omega-3 fatty acids have an impact on the immune 
response. Long-term feeding of diets enriched in EPA and DHA decreases the production of 
cytokines involved in the pro-inflammatory aspect of inflammation like IL-1β, TNFα, and IL-6 
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[22]. A daily teaspoonful of fish oil given to healthy Danish infants for 3 months markedly 
increased the omega-3 fatty acid content of their red blood cell membranes. EPA is the precursor of 
the pro-resolution lipid mediator resolvin E1 (RvE1) and DHA is the precursor of resolvin D1 
(RvD1) and protectin D1 (PD1). At nanomolar levels RvE1 dramatically reduces transendothelial 
migration of human PMNs and thus promotes resolution of inflammation [23]. RvD1 and PD1 have 
pro-resolution effects especially in reduction of PMN infiltration in murine skin air pouch 
inflammation [24], peritonitis [25] and brain injury [26]. Additionally PD1 promotes corneal 
epithelial wound healing and repair [27] and reduces airway inflammation in a mouse model of 
asthma [28]. These chemical mediators have thus been shown to control the magnitude and duration 
of inflammation in animals and function as an agonist in the different steps of the resolution of 
inflammation [23]. 
 
AA is part of the omega-6 fatty acids and derives from the linoleic acid which can be found 
in vegetable oils. Upon various physiological stimuli, AA is released by phospholipase A2 (PLA2) 
from membrane phospholipids stores. Cyclooxygenases convert AA into prostaglandins, 
prostacyclins and thromboxanes, whereas lipoxygenases generate leukotrienes and lipoxins. During 
the initial phase of inflammation, the pro-inflammatory lipid mediator prostaglandins and 
leukotrienes are produced. Both act as a paracrine and autocrine lipid mediator. The prostaglandins 
are formed by most cells in our body, induce pain, vasodilatation and fever and are the first target of 
the non-steroid anti-inflammatory drugs (NSAID). Prostaglandins like PGE2 and PGD2 have been 
shown to have pro-inflammatory actions in regulating blood flow, vasodilatation and permeability 
of the endothelium to help leukocytes undergo adhesion and diapedesis to the site of inflammation 
[29]. Along these lines, leukotrienes contribute to the recruitment of neutrophils toward the site of 
inflammation to mediate pathogen killing. Once inflammation is initiated, inflammatory events are 
amplified in a cascade loop until the infection/injury is contained via immune reactions. Therefore it 
is crucial for the body to stop pro-inflammatory signals and start resolution mechanisms. To do so, 
PGE2 and PGD2 actively switch the transcription of enzymes required for the generation of lipoxins, 
resolvins and protectins (Fig.1a) [30]. The function of the lipoxins is to promote resolution of 
inflammation by reducing PMN infiltration [31], to stimulate nonphologistic monocyte recruitement 
that seems to be required for wound healing [32] and to promote the removal of apoptotic PMNs by 
macrophages [33]. 
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 Fig.1: Switch of lipid mediators over time in inflammation [34] 
(a) Sequence of lipid-der tion) towards resolution 
 
1.2.2 Biosynthesis of Leukotriene B4 and the cysteinyl leukotriene LTC4, LTD4 and LTE4 
The capacity to generate large amounts of leukotrienes from AA is largely limited to 
leukocy
ived mediators modulating acute inflammation from onset (initia
(termination, return to homeostasis). (b) Lipid mediators controlling influx into the inflammation site: the pro-
inflammatory mediators PGE2, PGI2 and leukotriene LTB4 increase the further recruitement of leukocytes at the 
inflammation site and with time, a class-shift occurs towards pro-resolving mediators LXA4, RvE1 and PD1 that block 
leukocyte extravasation into the inflammation site. 
 
tes. The leukotrienes are the products of the 5 lipoxygenase (5LOX), which is expressed 
predominantly by PMNs, mast cells, B-lymphocytes, dendritic cells and macrophages. Initially, 
cells can be activated by immune complexes, bacterial peptides and other stimuli, which elicit the 
translocation of PLA2 to the nucleus. The primary step in the synthesis of leukotrienes is the 
cleavage of the arachidonyl ester bound in membrane glycerophospholipids through the action of 
the cytosolic PLA2α (cPLA2α). cPLA2α is fully activated by submicromolar concentrations of 
calcium (Ca2+) [35] and releases free AA in a hydrolysis reaction. The importance of this enzyme 
was demonstrated in cells deficient in cPLA2α that showed an almost complete inability to 
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synthesize prostaglandins or leukotrienes in response to a variety of stimuli [36]. Once released, 
free AA has different fates and can be presented to different enzymes. Among these enzymes are 
the cyclooxygenase 1 and 2 (COX1, COX2), which metabolize AA into the intermediate 
prostaglandin H2 (PGH2). PGH2 is in turn converted into the others prostaglandins; PGD2, PGE2, 
PGF2 and PGI2. Another enzyme which can transform AA is the 5LOX, which is expressed only in 
cells of myeloid origin [37]. 5LOX has a NH2-terminal domain that binds two calcium ions in 
response to increased concentrations of Ca2+. The large catalytic domain of 5LOX contains an iron 
ion that is essential for the initial hydrogen abstraction process. 5LOX not only catalyzes the 
conversion of AA to 5-HPETE but also the following step to the formation of epoxide leukotriene 
A4 (LTA4). 5LOX is assisted by the five lipoxygenase activating protein (FLAP) that enhances the 
ability of 5LOX to interact with its substrate. Although FLAP does not have enzymatic activity by 
itself, it was found to be expressed in cells that synthesized leukotrienes but not cells lacking 5LOX 
[38]. LTA4 is then transferred by intercellular mechanisms to different cells, which determine what 
kind of pathways is used to transform LTA4. For instance, during the interaction of the endothelial 
cells with the PMNs, the leukotriene C4 synthase (LTC4S) catalyzes LTA4 conjugation with 
glutathione to form LTC4 [39, 40]. When platelets are incubated with LTA4 they participate in 
LTC4 biosynthesis [40, 41]. Once exported out of the cells, LTC4 is subjected to extracellular 
metabolism forming leukotriene D4 (LTD4) which undergoes conversion to leukotriene E4 (LTE4) 
by sequential amino acid hydrolysis. In another pathway, LTA4 is taken up by erythrocytes or 
alveolar macrophages and is hydrolytically attacked by the LTA4 hydrolase to produce leukotriene 
B4 (LTB4) [42-44]. To perform their particular function, leukotrienes act through specific G-protein 
coupled receptors, which are members of the rhodopsin family and are located on the outer plasma 
membrane of inflammatory cells. Mostly they elicit changes in intracellular calcium and cyclic 
AMP concentrations which have an effect on downstream kinase cascades and lead to pro-
inflammatory actions. There are two subtypes of cysteinyl leukotriene receptors, CysLT1 and 
CysLT2 that mediate actions of LTC4 and LTD4. CysLT1 and CysLT2 are expressed in airway 
SMCs [45, 46] where they promote bronchoconstriction, edema and mucus secretion. LTB4 binds to 
specific receptors BLT1 and BLT2 that colocalized with markers for macrophages, endothelial cells 
and vascular SMCs in human carotid artery atherosclerotic plaques [47]. In monocytic cells, LTB4 
increases IL-6, MCP-1 and TNFα mRNA expression via a NF-kB-dependent mechanism, which 
promote pro-inflammatory and chemoattractant actions [48].  
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1.2.3 Biosynthesis of Lipoxin A4 
 
Lipoxins are produced locally at sites of inflammation. The lipoxin series were first isolated 
from human leukocytes and were found to be conserved across species [49, 50], indicating a high 
biological significance across evolution. Typically, lipoxins are generated by a transcellular route. 
Interaction of PMNs with platelets or resident tissue cells such as epithelial cells is a good 
illustration of such a cell-cell interaction and demonstrates the signalling complexity of lipoxin 
formation. [51]. As for leukotrienes, AA is their precursor and the combined action of two or more 
lipoxygenases, the 5LOX and 15-lypoxygenase (15LOX) or 12-lypoxygenase (12LOX) produce 
lipoxins by one of at least three biosynthetic pathways. Interestingly biosynthesis of lipoxins 
concomitantly blocks the formation of leukotrienes at the 5LOX level [52], leading to an opposite 
regulation of lipoxin and leukotriene biosynthesis (Fig.1b). 
 
1.2.3.1 15LOX pathway 
 
The first described biosynthetic route for the generation of lipoxins involves insertion of 
molecular oxygen into carbon (C) 15 position of arachidonic acid by the 15LOX to generate 15S-
HETE, which can be stored in lipid membranes (Fig.2) [53]. 
Fig.2: 15LOX pathway of the lipoxin biosynthesis [53] 
In monocytes or epithelial-cell, 15-LOX transforms AA into 15 S-HETE which can then serve as a substrate for 
neighbouring leukocytes. 5-LOX generates 5,6-epoxytetraene which is converted to LXA4 and LXB4 by hydrolases. 
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Along these lines during the course of inflammation, activation of the cells release 15S-HETE, a 
product that inhibits PMN migration across cytokine-activated endothelium in vitro by reducing 
LTB4 triggered stimuli [54]. Neighbouring leukocytes take up 15S-HETE, which is transformed 
into the 5(6) epoxytetraene. The action of specific hydrolases rapidly converts this intermediate in 
lipoxin A4 (LXA4) and lipoxin B4 (LXB4) that are released in the micro-environnement to complete 
their anti-inflammatory functions  [55].  
 
1.2.3.2 5LOX pathway: 
 
The second source of lipoxins comes from the vasculature, mainly from the interaction 
between PMNs and platelets. Oxygenation of AA at the carbon 5 position by the 5LOX in PMNs 
leads to the formation of 5-HpETE which is rapidly converted into LTA4 (Fig.3). It appears that 
unprimed PMNs do not generate lipoxins on theirs own and biosynthesis of lipoxins by this route 
needs the interactions with other cells. About 50% of the LTA4 is released by PMNs and could be 
taken up by human platelets to form LXA4 and LXB4 [56, 57]. The molecular profile of cell-cell 
interaction is of primary importance for lipoxin formation because transcellular biosynthesis needs 
cells adhesion. Indeed mice deficient in the adhesion molecule P selectin have a reduced efficiency 
of transcellular lipoxin generations, which was restored with infusion of wild-type platelets in a 
model of glomerular nephritis [58, 59].  
Fig.3: 5LOX pathway of the lipoxin biosynthesis [53]. 
5-LOX in PMNs metabolizes AA to LTB4, which is taken up by platelets in a transcellular manner and converted by 
platelet 12-LOX to LXA4. 
 
1.2.3.3 Aspirin-triggered lipid (ATLs) pathway: 
 
The third pathway involves the covalent acetylation of a serine residue on COX2 by 
aspirin, which inhibits prostaglandin formation. The acetylated COX2 converts AA in endothelial 
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cells into 15R-HETE, a metabolite that has the C15 alcohol in R configuration (Fig.4). This is due 
to an unusual L-shaped binding of AA with COX2 [60]. Interaction of this intermediate metabolite 
with PMNs leads to the formation of 15-epi-LXA4 and 15-epi-LXB4 resulting from the action of 
5LOX. 15-epi- LXB4 seems to be an inhibitor of cell proliferation. Moreover in healthy individuals 
15-epi-LXA4 is produced when low dose of aspirin is taken [61] and has been proven to be a more 
potent inhibitor of neutrophils adhesion than LXA4 [62]. 
Fig.4: Aspirin-triggered lipid pathway of the lipoxin biosynthesis [53] 
Aspirin acetylates the active site of COX2 resulting in the conversion of AA to 15R-HETE which when released from 
endothelial and epithelial cells is transformed by PMN 5-LOX to generate 15-epi-LXA4 or 15-epi-LXB4. 
 
1.2.4 Lipoxin A4 Bioaction: 
 
Native LXA4 is sensitive to metabolism by prostaglandin dehydrogenase and is rapidly 
inactivated. In contrast, the epi-lipoxins generated via the action of aspirin or synthetically produced 
(LXA4 analogues) are more stable [63] and therefore have been widely used for elucidating their 
bioactions. In general lipoxins block the production and action of LTB4 and LTC4 in human 
leukocytes [64, 65]. 
More precisely, one of the main functions of lipoxins is to inhibit PMNs recruitment, 
chemotaxis and transmigration across the endothelium which are hallmarks of the anti-
inflammatory process. Indeed PMN transmigration across polarized epithelial cell monolayers, as 
well as adhesion to vascular endothelial cells, was inhibited by different types of LXA4 analogues 
[63]. LXA4 and LXB4 block PMN migration by inhibiting β2 integrin-dependent PMN adhesion 
and P-selectin mobilisation from the Weibel-Palade bodies, which mediates PMN endothelial cell 
adhesion [66]. Furthermore, LXA4 analogues reduce leukocyte rolling and adherence by attenuating 
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P-selectin expression [67]. LXA4 chemotaxis function was also confirmed in animals. Despite 
excessive PMN recruitment in BLT1 transgenic mice, intravenous injection of ATLs sharply 
diminished reperfusion-initiated PMN trafficking. Furthermore topical application of lipoxins was 
protective in a model of acute dermal inflammation [68] and markedly inhibited PMNs infiltration 
in mouse ears [69, 70] and murine air pouches [71]. Serhan and coworkers also generated 15LOX 
transgenic rabbits and subjected them to periodontitis. In this study, topical application of LXA4 
stable analogues dramatically reduced leukocyte infiltration and inflammation [72]. Moreover in 
rats LXA4 analogues dramatically blocked allergic pleural eosinophil influx with both inhibition of 
eotaxin and IL-5 generation as well as platelet activating factor [73]. Finally, administration of a 
synthetic cannabinoid in vitro to human blood and synovial cells increased LXA4 production and 
resulted in a 25 to 75% reduction of cells invading the peritoneum in a mouse model of peritonitis 
[74]. 
LXA4 reduces leukocytes chemotaxis in particular through regulation of chemokines. For 
example, in fibroblast  and in pulmonary microvascular endothelial cells (PMVEC), LXA4 inhibits 
IL-8 expression [75, 76] as well as IL-8 secretion in a model of Salmonella typhimurium infected 
T84 intestinal epithelial cells [77]. IL-8 is a strong chemoattractant for leukocytes and is heightened 
in severe asthma, where it increases eosinophil recruitment. Results from two groups of patients 
with asthma revealed that LXA4 and LXB4 inhibit the IL-8 release by peripheral blood mononuclear 
cells [78]. Furthermore the administration of LXA4 analogues blocked both airway hyper-
responsiveness and pulmonary inflammation by decreasing IL-5 and cyteinyl leukotrienes [79], 
which are both chemoattractants for eosinophils. LXA4 not only reduces chemokine but also 
cytokine expression. Indeed LXA4 prevents the elevation of pro-inflammatory cytokines such as IL-
12 and IFNγ in animals exposed to T.gondii [80] and reduces both L-selectin and CD11/CD18 
expression in mouse dermatitis induced by LTB4 [81]. 
Another function of LXA4 is the inhibition of superoxide production. Superoxides are 
byproduct of the mitochondrial respiration and are used by the immune system to kill invading 
microorganisms. Inhibition of their production has been shown in several cell types, for example, 
addition of 1-10nM of LXA4 and ATL analogues inhibit TNFα–stimulated superoxide anion 
production and IL-1β release by human leukocytes [71]. Furthermore higher concentrations of ATL 
(1-100nM) completely blocked reactive oxygen species production in endothelial cells [82]. In 
PMN, 15-epi LXA4 reversed LTB4-initiated presqualene diphosphate production that regulates 
superoxide anion generation [83, 84] and selectively downregulated PMN release of azurophilic 
granulae [85]. Similarly in monocytes and RAW264.7 macrophages, LXA4 analogues markedly 
reduced LPS-stimulated superoxide formation. This process was accompanied by an attenuation of 
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nuclear accumulation of AP1 and NF-kB, two transcription factor critical for vascular events [84, 
86]. 
Another main function of LXA4 is to stimulate phagocytosis of apoptotic PMN by 
macrophages. This observation was associated with actin rearrangement in THP-1 cells [87] and 
with an increased production of TGFβ, a negative regulator of immunity [88]. In mouse models of 
acute lung injury, 15-epi-LXA4 accelerated the resolution of PMN-dependent pulmonary 
inflammation through redirecting PMNs to caspase-mediated cell death and facilitating their 
removal by macrophages [89]. 
 
1.3  Lipoxin A4 specific receptor 
 
1.3.1 Molecular characteristic of ALXR 
 
Twenty years ago the receptor for the lipoxin A4 (ALXR) was considered a formyl peptide 
receptor (FPR1) because of its DNA sequence homology and thus was named FPRL1 [90] FPRH1 
[91] or FPR2 [92]. Indeed the cDNA of FPR2 was cloned from HL-60 neutrophils and its sequence 
shares 69% of identity with the FPR1 [90]. Since then, another gene that can cross-hybridized under 
high stringency conditions with both FPR1 and FPR2 was isolated and named FPR3 which shares 
56% of sequence with FPR1. All of them were mapped using a panel of somatic cell hybrids to the 
human chromosome 19 (19q13.3-19q13.4) [91] in a cluster that span 80kb, suggesting that they 
may have related biological functions and may share pharmacological properties. The human FPR2 
mRNA is 2.1kb long and was cloned in several types of cells including monocytes [93] and T-cells 
[94], as well as resident cells such as macrophages, synovial fibroblasts [75] and intestinal epithelial 
cells [95]. The 351 deduced amino acid sequences indicated that FPR2 belongs to the class A 
rhodopsin GPCR superfamily (www.iuphar-db.org) characterized by seven putative transmembrane 
segments with N terminus on the extracellular side of the membrane and the C terminus on the 
intracellular side [93, 96, 97]. The rhodopsin superfamily contains the largest number of receptors 
that are targeted by clinical drugs [98] and binds a great number of ligands such as peptides and 
lipid-like compounds. The superfamily is divided into four groups (α, β, γ, δ) and the FPR members 
belong to the chemoattractant receptors of the γ group which includes receptors for leukotrienes, 
chemokines and thromboxanes. Protein sequence alignment shows that the first and second 
transmembrane domains are the highest conserved regions between FPR1, FPR2 and FPR3, 
followed by the seven transmembrane domains (Fig.5) [99]. 
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Fig.5: Alignement of the protein sequences of the human FPRs [99] 
The putative transmembrane domains I to VII are shaded. Comparison of the three receptors has identified highly 
conserved regions, including most of TM-I and TM-II, and the short intracellular loop connecting TM-I and TM-II, 
followed by the TM-VII. The second intracellular loops from these receptors, known for G protein interaction, are also 
nearly identical. 
 
Usually, extracelullar and transmembranes domains are important for ligand binding while 
intracellular domains are important for signal transduction and for feedback modulation of receptor 
function [100]. Among the FPR family, the second intracellular domain, known for G protein 
interaction, is identical whereas the extracellular loops differ between the receptors, suggesting 
difference in the nature of ligands that bind each receptor. Furthermore, the stretch of serine and 
threonines on the C terminal is conserved indicating that all receptors are desensitized via 
phosphorylation [101]. N-formyl peptide derived from bacteria and mitochondrial were identified in 
the mid 80’s to be the shortest peptides that initiate phagocyte functions [102, 103]. The first 
agonist identified for FPR2 was the synthetic N-formyl-MET-LEU-PHE (fMLP) peptide. However, 
this ligand only binds with low affinity to the FPR2 with a Kd of 1μM [92] whereas LXA4 binds to 
FPR2 with a Kd of 1.7nM [97]. Furthermore Fiore and coworker demonstrate that 3H LXA4 binds 
to PMN with a Kd of 0.5 nM [104]. Together these results suggest that LXA4 is a specific ligand of 
FPR2. Thus in an effort of simplicity and to avoid any confusion ALXR will be the name used in 
this thesis. 
ALXR orthologs have been identified in other primates [105], rats [106] and mice [107]. 
Mouse Fpr-rs1 and Fpr-rs2 are structurally similar to human ALXR [108] and the overall identity 
was found to be 76% on the nucleotide and 73% on the amino acid levels [69], which revealed good 
conservation of this gene between species. The gene product of Fpr-rs2 responds to several peptide 
agonists that activate human ALXR [109, 110]. Furthermore, the mouse Fpr-rs1 displays specific 
3H LXA4 binding when expressed in CHO cells and initiates LXA4 mediated GTPase activity [69]. 
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Thirty years ago it was found that PMN responses to formyl peptide was inhibited by pertussis 
toxin which ADP-ribosylates the G inhibitory (Gαi) class of heterotrimeric G proteins [111]. Like 
formyl peptide, LXA4 stimulates both GTPase and the release of esterifed AA in a pertussis-toxin-
sensitive manner [112]. Taken together these results indicate that ALXR interacts with the G 
protein Gαi to mediate its specific actions. 
 
1.3.2 ALXR regulation 
 
1.3.2.1 Transcriptional regulation of ALXR 
 
The transcriptional regulation of ALXR and the presence of splice variants are poorly 
described, since the promoter has not yet been characterized. However some regulators such as 
cytokines which control the expression of the ALXR mRNA have been identified. Gronert and 
coworkers have shown that the pro-inflammatory IFNγ and the anti-inflammatory IL-13 cytokines 
are the most potent inducers of ALXR expression in enterocyte (T84 cells). After 24h exposure, 
they increased ALXR mRNA 6,8 and 8.6 fold, and after 48h by 17.3 and 8.4 fold, respectively [95]. 
IL1β and LPS were the least potent pro-inflammatory cytokines, inducing a 1.8 fold increase in 
ALXR mRNA whereas exposure to the anti-inflammatory IL-4 or IL-6 cytokines increased receptor 
messenger levels by 3 fold. ALXR, therefore, can be regulated by pro and anti-inflammatory stimuli 
in those enterocyte cell lines depending on the micro-environment of the receptor. In synovial 
fibroblasts treatment with TNF-α and IL-1β was shown to up-regulate ALXR mRNA expression in 
a time-dependent manner whereas IL-6 had little effect on ALXR mRNA levels in these cells [113]. 
An inverse correlation was also found between ALXR expression and TXA2 signaling in a mouse 
model of lung fibrosis and in mouse macrophages [114]. Such an anti-inflammatory character of the 
receptor was also described in independent studies of other laboratories. For example the 
glucocorticoid hormone dexamethasone has been shown to up-regulate the expression of ALXR 
mRNA in human PMNs in a dose-dependant manner. In contrast, the glucocorticoid receptor 
antagonist mifepristone suppressed the induction of ALXR mRNA by dexamethasone, indicating 
that the signaling via glucocorticoid receptor plays a direct role in PMNs [81]. In a parallel study, 
incubation of human monocytes with dexamethasone or other synthetic glucocorticoids induced the 
de novo synthesis of ALXR, leading to an increase in mRNA levels after 4–6 hours and protein 
levels after 12–24 hours [115]. This transcriptional regulation demonstrates that the ALXR 
expression responds to anti-inflammatory stimuli and may have an essential and pro-resolving role 
during the course of inflammation. 
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1.3.2.2 Post-transcriptional regulation of ALXR 
 
GPCRs are regulated and exist in a equilibrium between two states, an inactivated (R) and 
an activated (G) [116]. Full agonist binding induces active conformation of the receptor which then 
couple with G proteins that transmit signals further to effector proteins in the cell. Negative 
regulation of the GPCRs exists to dampen cellular responses to the agonist and are referred as 
desensitization, sequestration and recycling or degradation of the receptor [100]. Desensitization is 
initiated by phosphorylation of the receptor by G-protein-coupled receptor kinases. Homologous 
desensitization was observed for ALXR as it is phosphorylated in a agonist dependent manner on 
the C terminal serine and tyrosine [117]. ALXR is capable of heterologous desensitization of other 
receptors like CCR5 and CXCR4 [118, 119] and does attenuate the cell response to their specific 
chemokines. Furthermore ALXR dephosphorylated  the platelet-derived growth factor receptor beta 
(PDGFRbeta) via SH2 domain-containing tyrosine phosphatase-2 (SHP-2) to promote anti-
inflammatory action on renal inflammation [120]. Usually receptor phosphorylation is followed by 
binding of the arrestins to uncouple the receptor with G proteins and to internalize the receptor into 
clathrin-coated vesicles. ALXR was shown to colocalize with β arrestin in HEK cells stimulated 
with the synthetic agonist peptide WKYMVM. Mouse embryonic fibroblast that lack β arrestin 
compromised ALXR internalisation [121]. Moreover, ALXR needs the large GTPase dynamin to be 
endocytosed which suggests a clathrin dependent sequestration. ALXR co-localizes with 
endocytosed transferrin and the small GTPases Rab4 and Rab11 in perinuclear recycling endosomes 
[122], indicating a slow recycling process which would target the ALXR receptor to degradation 
into lysosomes [123]. Rapid recycling to the plasma membrane has not been yet observed for 
ALXR. Interestingly, tertiary gelatinase granules of PMNs are reported to be potential stores of 
ALXR which are mobilized upon stimulation by LPS and other pro-inflammatory stimuli [124, 
125]. Taken together, these results suggest that post-transcriptional regulation of ALXR is an 
important aspect of the function of the receptor and might be critical during the course of 
inflammation. 
 
1.3.3 Pro and anti-inflammatory ligand of ALXR 
 
Ligand diversity is an important aspect of the FPR family receptors. In this regard, ALXR 
binding pocket may be large and flexible enough for proper contact with a variety of ligands. 
Results obtained from different experiments indicate that specific peptides as well as lipid 
mediators can both function as ligands for the same receptor. ALXR can recognize several short-
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lived lipids, such as lipoxin A4 and its stable analogues, as well as proteins and peptides, such as 
serum amyloid protein A (SAA) and those derived from viral glycoproteins (Fig.6). Interestingly, 
receptor N-glycosylation, which is important for ligand specificity, is present on two asparagines of 
the ALXR (Asn 4 and Asn 179) and deglycosylation reduces peptide affinity and recognition for 
ALXR. The property, that fMLP binds with low affinity ALXR, was used for mapping the ALXR 
ligand binding domain. Seven chimeric FPR1/ALXR and three chimeric ALXR/FPR1 receptors 
were constructed by selective substitution of one receptor’s fragment into the other receptor. The 
results show that the first and third extracellular loops are essential for high affinity binding of 
fMLP [126]. Conversely chimeric receptors constructed from the receptor BLT1 and ALXR 
revealed that the seventh transmembrane segment and adjacent regions of ALXR are essential for 
LXA4 recognition [127]. Theses two independent results suggest that ALXR has different binding 
pocket related to the nature of the ligand.  
Fig.6: Pro- and anti-inflammatory ligands of ALXR [128] 
Both peptide and lipid-derived ligand bind to ALXR to modulate pro- and anti-inflammatory actions. 
 
During the pro-inflammatory phase, host response to injury and infection is accompanied 
by a rapid rise in the blood of acute-phase proteins like serum amyloid A (SAA). Ten years ago, 
SAA was one of the first pro-inflammatory chemotactic ligands identified for ALXR [129] which 
led to the increase of IL-8 secretion following activation of NF-kB in human PMNs [130]. SAA 
induced via ALXR other pro-inflammatory actions such as matrix-metalloproteinase 9 (MMP9) 
generation [131] and chemokine CCL2 production in a concentration-dependent manner in human 
monocytes [132]. Since the discovery of SAA as a pro-inflammatory ligand for ALXR, more 
peptide/proteins were identified as ligands for ALXR. For example, cleavage of the chemokine 
CCL23 by a protease present during inflammation releases a 18 amino-acid peptide (SHAAGtide) 
which recruits monocytes and PMNs in vitro via ALXR [133]. Moreover, bacteria-derived peptides 
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like Helicobacter pylori derived peptide Hp-(2-20) can activate ALXR  [134] as well as synthetic 
peptides like MMK-1, which induces chemotaxis and calcium mobilization in leukocytes [135-
137]. MMK-1 activates PMNs to produce and release superoxide anions through release of Ca2+ 
from intracellular stores and through opening of ion channels in the plasma membrane [138]. 
Finally, in brain tissue of neurodegenerative Alzheimer disease’s patient ALXR is expressed at high 
levels on inflammatory cells infiltrating senile plaques and signals a chemotatic response to beta 
amyloid peptide (Aβ42) [139]. To conclude, these pro-inflammatory peptides/proteinS do not share 
apparent homology in terms of the primary amino acid sequences and further investigation of their 
role in human pathology has not been yet determined. However, they were shown to induce 
inflammatory actions through ALXR, which might therefore play a role in the pro-inflammatory 
phase of inflammation. 
The anti-inflammatory effects of ALXR became apparent when LXA4 was identified as an 
endogenous ligand for ALXR. Using freshly isolated radioligands, specific LXA4 binding sites 
were characterized on isolated human PMNs and demonstrated to be responsible for the specific 
LXA4 function [104]. Synthetic 15-epi-LXA4 and LXA4 have shared stereospecific actions for 
activating ALXR-regulated gene expression and for their ability to inhibit human PMN migration 
through endothelial cells [140, 141]. Indeed LXA4 has been shown to decrease SAA-induced IL-8 
secretion [130, 142] and 15-epi-LXA4 inhibits VCAM and E-selectin expression in endothelial cells 
[143]. In addition to the inhibition of PMN chemotaxis and migration, LXA4 inhibited TNFα 
secretion by T cells [94], induced chemotaxis of monocytes without cytotoxicity [93] and has been 
shown to promote nonphlogistic phagocytosis of apoptotic PMNs by human macrophages [18, 33, 
144]. The glucocorticoid-induced Annexin A1 (ANXA1) and its derived peptide Ac2-26, generated 
in vivo, could also halt PMN diapedesis. Both of these anti-inflammatory responders were shown to 
interact directly with recombinant human ALXR in human embryo kidney cells transfected with 
ALXR and in primary PMNs [145]. In another study Gavins and co-workers demonstrate that 
ANXA1 inhibited firm adhesion of human PMNs, while Ac2-26 significantly attenuated capture 
and rolling [146]. Recently in vivo data confirmed the anti-migratory action of ANXA1 in knock 
out mice and the co-localization of ALXR with ANXA1 in PMNs that migrate into the mesenteric 
microcirculation [147]. Thus ALXR possibly induces anti-inflammatory actions when pro-resolving 
mediators such as LXA4 and ANXA1 are present during the late phase of inflammation. 
The dual role of ALXR as a pro-inflammatory or anti-inflammatory receptor is supported 
by the opposite actions of ALXR during HIV infection. In one way ALXR is a co-receptor for 
HIV/SIV [148] helping HIV to target and enter cells but in another way a synthetic peptide domain 
of the V3 region of the HIV-1 envelope gp120 activates ALXR in monocytes [149] which resulted 
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in the downregulation of the HIV-1 chemokine co-receptors CCR5 and CXCR4 [150], therefore 
blocking HIV-1 entry. Furthermore, depending on the cell types, the same ligand can induce 
different effects via ALXR. In fibroblast LL-37 generates superoxide generation with activation of 
the NADPH oxidase [151] while in PMNs, it was found to inhibit the pro-inflammatory actions of 
SAA via inhibition of ERK and p38 MAPK activity [152]. 
The finding that specific endogenous lipid mediators and certain peptides interact with the 
same receptor may reflect at the genomic level the economy of using one receptor structure for 
multiple recognitions and functions in the immune system. Furthermore, competition between these 
pro and anti-inflammatory agents points towards an important role of ALXR during the onset of 
chronic inflammatory diseases and its resolution. 
 
1.3.4 LXA4-ALXR downstream signaling 
 
The current understanding of the ALXR’s signal transduction pathways remains incomplete 
and there are no clear mechanisms of the pathway that explain the pro- and anti-inflammatory 
functions of the receptor. Receptor dimerization upon ligand binding could be observed for 
leukotriene and chemokine receptors but no study reported ALXR homo or hetero dimerization 
[153, 154]. GPCRs activation induces guanosine diphosphate GDP release (inactive state) and 
guanosine triphosphate GTP binding (active state) to a heterotrimeric G protein that is dissociated 
into Gβγ protein and Gα protein. Gα protein is the effector protein that possesses GTPase activity 
and transmits downstream signals in the cells. LXA4 binding to ALXR was shown to stimulate 
GTPase activity [112] and to increase the intracellular content of Ca2+ followed by the activation of 
phospholipase A2 and phospholipase D [93]. All of these responses were shown to be sensible to the 
treatment with the specific Gi inhibitor PTX which stops the production of cyclic adenosine 
monophosphate (cAMP) from ATP by decreasing adenyl cyclase activity. This enzyme induces 
normally cAMP dependent protein kinase A  which phosphorylates other proteins and is important 
for cell cycle and carbohydrate and lipid metabolism.  
LXA4 binding to ALXR has been shown to promote monocyte chemotaxis without 
increasing cell-mediated cytotoxicity and reactive oxygen generation. These effects are typically 
anti-inflammatory actions that are needed to reduce the pro-inflammatory state and to restore tissue 
homeostasis. An interesting study investigated the downstream signaling of ALXR when ATL1 are 
used to induce human monocyte chemotaxis. ATL1 bound to ALXR activated the Gαi protein that 
triggered Ras homolog gene kinase dependent pathway (Fig.7). The Rho kinases induce 
phosphorylation of the extracellular signal-regulated kinases (ERK-2), a member of the mitogen-
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activated protein kinase (MAPK) family. This observation was consistent with previous studies 
which showed that distinct peptide ligands increased ERK-2 phosphorylation through the activation 
of ALXR [132, 155]. In this study ATL1 also increased myosin light chain kinase (MLCK) 
phosphorylation in an ERK2 dependent fashion, suggesting that MLCK could be a downstream step 
of the MAPK pathway in monocytes. MLCK can then phosphorylate the myosin light chain (MLC), 
which promotes cytoskeleton contraction necessary for cell movement. A Rho kinase inhibitor Y-
27632 abrogated both MLCK phosphorylation and chemotaxis stimulated by ATL-1, indicating that 
the Rho/Rho kinase pathway may be necessary for ATL-1-induced monocyte chemotaxis via 
MLCK. Therefore, Simon and co-workers hypothesized that ATL1 acting via ALXR promotes 
monocytes chemotaxis through polymerization of actin cables [156]. 
 
Fig 7: ALXR chemotaxis downstream signaling [156] 
ATL-1 occupies ALXR, which results in the activation of the Rho/Rho-kinase pathway. Rho-kinase phosphorylates 
ERK-2 and MLCK, leading to the induction of MLC and actin rearrangement, which permit cell chemotaxis. 
 
Another important function of LXA4 is to induce the removal and phagocytosis of 
apoptotic PMNs by human macrophages in inflamed tissue. Cell clearance is an essential step of the 
resolution phase of inflammation. A recent study investigated the ALXR downstream signaling and 
proposed a pathway for the pro-apoptotic action of ALXR in PMNs, which are rapidly removed 
from the tissue. The authors suggest that LXA4 and ATL inhibit and override the survival signals 
from SAA. Indeed SAA induces the PI3kinase and MEK pathways which evoke rapid 
phosphorylation of the protein kinase Akt and ERK1/2 respectively (Fig. 8). Both pathways activate 
the proapoptotic B-cell lymphoma 2 (Bcl2)-associated death promoter protein (Bad) which is 
dissociated from the antiapoptotic myeloid leukemia cell differentiation protein (Mcl1). Mcl-1 
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prevents the loss of mitochondrial transmembrane potential which normally releases cytochrome c 
and activates caspase 3, a activator of apoptosis [157]. Thus SAA reduces apoptosis and prolonges 
the survival of PMNs. These effects have been shown to be inhibited by LXA4 and ATL-1 actions 
through ALXR which therefore, promotes pro-resolution mechanisms. 
Fig.8: ALXR apoptosis downstream signaling [157]. 
SAA binds to the protein-binding domain of the FPRL1/ALX and induces phosphorylation of the proapoptotic protein 
Bad through activation of the PI-3K/Akt and MEK/ERK pathway. Phosphorylated Bad then dissociates from Mcl-1, 
preventing the collapse of mitochondrion ΔΨm, cytochrome c release, and activation of caspase-3, characteristic features 
of PMNs undergoing constitutive apoptosis. LXA4/ATL binds to the lipid-binding domain of FPRL1/ALX and over-
rides the SAA survival signal and redirects PMNs to apoptosis. 
 
1.3.5 ALXR evidence in animals and human disease 
 
Recently, an interesting study described for the first time ALXR knock out mice which were 
more sensitive to inflammation with a pronounced increase in cell adherence and emigration in the 
mesenteric circulation after ischemia-reperfusion insult. This study showed that SAA stimulated 
PMNs recruitment whereas LXA4 and Ac2-26 had anti-migratory effect on the same cells, 
indicating that ALXR can have pro-inflammatory actions which are inhibited in the presence of 
strong competitors like LXA4 and Ac2-26 [158]. The anti-inflammatory effect of the ALXR is also 
supported in transgenic mice that expressed human ALXR which led to a significant inhibition of 
pulmonary inflammation and eicosanoid-initiated eosinophil tissue infiltration [79]. Reduced PMN 
infiltration was also observed in mice following dermal ear inflammation [159] and acute lung 
injury [160]. Furthermore, in inflammatory hyporesponsiveness mice administration of a 15-epi-
LXA4 analogues or an annexin-1-derived peptid prevented tissue injury, TNFα production, and 
lethality after intestinal ischemia/reperfusion. This process was associated with the release of IL-10 
production and was reversed by treatment of the mice with an antagonist of ALXR (BOC1) [161]. 
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Together these data indicate that ALXR is an important modulator of the outcome of inflammation. 
Resolution of inflammation is mediated by extracellular stimuli and the corresponding signals that 
cells transmit through receptor. Thus ALXR knock out and hALXR transgenic mice are of great 
importance to visualize the protective role of this receptor in the anti-inflammatory and pro-
resolution response relevant to human disease. ALXR is expressed in several human diseases such 
as dermatitis, where ALXR was found to be on membranes of PMNs which had exocytosed the 
content of their granules [162]. Furthermore, expression of ALXR is strong in rheumatoid arthritis 
[163] and in injured bronchial epithelials [164]. However, LXA4 and ALXR generation decreased 
in bronchoalveolar lavage fluid obtained from subjects with severe asthma as well as in peripheral 
blood granulocytes, like PMNs and eosinophils [165]. Thus, ALXR and its pro- and anti-
inflammatory agonist seem to be important players in inflammation and human disease and may 
give new approach for the therapeutic control of inflammation.  
 
1.4 Atherosclerosis 
 
Atherosclerosis is a wide-spread disease with a long asymptomatic phase and is the primary 
cause of cardiovascular disease CVD like coronary artery disease (CAD) leading to myocardial 
infarction MI (heart attack) and stroke (cerebrovascular attack) [166]. Atherosclerosis advanced 
lesions start at the age of 25 years and clinical manifestation occurs in 2 of 3 men and 1 in 2 women 
after age of 40 [167]. The common risk factors are multiple and include diabetes, cigarette smoking, 
dyslipidemia with high concentration of low-density lipoprotein cholesterol LDL-C and low 
concentration of high-density lipoprotein cholesterol HDL-C, hypertension, advanced age and 
family past history (www.agla.ch). Family history in atherosclerosis increases the risk of 
developing a cardiovascular event when the number of relatives or the age at which coronary heart 
disease (CHD) first becomes evident is taken into account [168]. 
Atherosclerosis is characterized with the formation of plaques that narrows the arteries (stenosis) 
and is visualized at angiography. Even though bacteria and virus-derived antigens have been found 
in atheroma lesions [169-171], a number of evidence suggests that when entering the arteries LDL-
C are modified by enzymes and oxygen radicals into oxidized LDL (oxLDL) which is recognized as 
foreign agent and leads to the activation of an inflammatory response [172]. PPRs implicated in 
atherosclerosis are TLR4 [173] or SRs such as SR-AI and CD36 which have been found to be the 
most important receptors in the uptake of oxLDL by macrophages [174, 175]. Excessive amount of 
circulating cholesterol elicits then an inflammatory response from arterial wall tissue. Endothelial 
cells have been shown to express VCAM-1 in response to cholesterol feeding in areas prone to 
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lesion formation [176]. Other chemokines and cytokines have been shown to be implicated in 
atherosclerosis such as E and P-selectin which contribute to leukocytes recruitment in 
atherosclerosis-susceptible mice [177] or ICAM in which genetic deletion inhibits atherosclerosis in 
mice [178]. Signaling molecules such as IL-1β, IL-12, IL-8, IL-6 and TNFα have been associated 
with an increased risk of CAD and recurrent MI [6-8]. Furthermore, endothelial function is 
impaired during atheroslcerosis via disruption of the endothelial nitric oxide synthase (eNOS) 
activity (Fig.9a). As a consequence, vasorelaxant nitric oxide (NO) production is impaired [179] 
and might lead to the development of premature atherosclerosis [180]. 
For a long time it was thought that PMNs were not present in plaque lesion and do not 
contribute to the pathogenesis of atherosclerosis. Nevertheless, recent evidence suggest that it is not 
the case and PMN infiltration was found in various intermediate and advanced stages of 
atherosclerosis in low density lipoprotein receptor deficient (LDLR-/-) mice [181, 182], in coronary 
lesions obtained at autopsy from patients with myocardial infarction [183] and in patients with 
unstable plaques. PMN count appears to be higher in such patients than those with stable disease 
suggesting a link between PMN infiltration plaque fragility and haemorrhage [184]. Prolonged 
PMN survival has been shown to be mediated by several factors like IL-6, IL-8, TGFβ and hypoxia 
and their apoptosis has been shown to be delayed in acute coronary syndrome, contributing to an 
exponential increase of inflammation [185]. Despite this prolonged survival of PMNs, they still 
undergo apoptosis and are taken up by monocytes-derived macrophages. However, in 
atherosclerosis macrophages take up also esterified cholesterol and are transformated into foam 
cells [186] which is the major cellular event contributing to fatty streak formation (Fig 9b) 
Transition from fatty streak to complex lesion is accompanied with the recruitment of SMCs 
from the media layer to the intima layer. (Fig.9c). SMCs proliferate and take up modified 
lipoproteins contributing to foam cell generation and collagen-derived fibrous cap formation [172]. 
In addition to the recruitment of SMC, angiogenesis and neovascularization are processed that serve 
at the site of inflammation to perform nutritive function and to promote plaque growth [187]. With 
the time, cells undergo programmed cell death resulting from cell-cell interaction and cytokine 
presence in the micro-environment. Macrophages are rapidly overloaded with apoptotic cells and 
lipids and release cell debris. Cells undergo into necrosis and form a lipid core that induces plaque 
instability [188]. Release of matrix metalloproteinase like MMP9 from macrophages degrades 
extracellular matrix proteins [189, 190] and pro-inflammatory cytokines like IFNγ starts to inhibit 
production of collagen by SMC [191].  
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Fig.9: Evolution of atherosclerosis [192] 
a. Activation of pro-inflammatory conditions leads to leukocyte adhesion and increased permeability of the 
endothelium. B. Monocyte-derived macrophages that are recruited to the intima accumulate lipids and transform into 
foam cells, which make up fatty streaks. c. Apoptosis of macrophages and other plaque cells create a necrotic core, and 
a fibrous cap that consists of matrix and a smooth-muscle-cell layer forms. Neovascularization can occur within the 
plaque and leakage of fragile vessels can lead to plaque haemorrhage. d. Thinning and erosion of the fibrous cap in 
unstable plaques because of matrix degradation by proteases, result in plaque rupture, with release of debris, activation 
of the coagulation system and plaque thrombosis of the artery. 
 
Finally, advanced atherosclerotic lesions lead to narrowing of blood vessels and to ischemic 
symptoms. Most myocardial infarction and stroke events are due to plaque rupture and thrombosis 
formation (Fig 9d). Indeed, endothelial desquamation can be observed, in which von Willebrand 
factor proteins recruit coagulation factor like Factor VII and collagen. This will promote platelet 
adhesion and activation of the coagulation system like thrombin-mediated fibrin production [193]. 
Blot clot formation and plaque rupture prevent blood flow and leads to ischemia of the myocardial 
muscle. Morbidity and mortality from atherosclerosis is largely due to disruption of unstable 
plaque, haematoma or haemorrhage and thrombotic deposit. 
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1.4.1 Lipid mediator in atherosclerosis 
 
The role of leukotrienes in atherosclerosis has been the subject of intense investigation in 
animals and in vitro studies in which they promote the recruitment of monocytes and differentiation 
into foam cell as well as intimal hyperplasia [194]. LTB4 receptor is expressed in cells that are 
involved in atherosclerosis [195] and treatment of LDLr-/- and apoE-/- deficient mice with a specific 
LTB4 receptor antagonist CP-105,696 for 35 days, significantly reduced the chemoattractant agent 
CD11B in both vascular lesions and whole blood [196]. Along these lines combination of BLT1-/- 
and apoE-/- knock out mice demonstrated a clear reduction of plaque formation compared to apoE-/- 
controls [197]. Also the LTB4 receptor genes have been intensely searched for genetic variant that 
would be associated with atherosclerosis. Recently haplotype in the LTB4 receptor complex was 
found to confer a 2.3 fold increase in risk of ischemic stroke [198]. Human arteries subjected to 
angioplasty and stent implantation displayed an increased intima/media thickness and higher MMP-
2 and -9 activities in the presence of LTB4 [199]. Moreover it was found that CysLT1 mediated 
vascular permeability and tissue fibrosis [200] and that an inhibitor of CysLT1 significantly 
decreased atherogenesis [201]. Furthermore, enzymes leading to the production of leukotrienes 
have been shown to be involved in the development of atherosclerosis. For instance, 5LOX is 
higher expressed in vulnerable plaques [202] and has been correlated with the severity of 
atherosclerotic lesions [203, 204]. Polymorphisms in the 5LOX promoter were found to be 
associated with increased intima-media thickness of the carotid artery [205] and with coronary 
disease [206]. FLAP was also identified as a susceptibility gene for myocardial infarction and 
stroke following a genome wide screen performed in Icelandic individuals [207]. Together these 
results indicate that leukotrienes and the enzymes, leading to their biosynthesis, are enhancers of 
atherosclerosis. 
It is now generally accepted that generation of anti-inflammatory lipid mediators is 
implicated in the resolution of inflammation. 15LOX is an enzyme expressed in eosinophils, 
alveolar macrophages, monocytes and epithelial cells [208, 209] and is a Janus enzyme with pro-
atherogenic and anti-inflammatory properties. There is indication that the 15LOX oxidizes LDL 
which is taken up by macrophages to develop foam cells. Additionally, overexpression of 15LOX in 
LDLr-/- deficient mice increased lesion formation and development [210]. However, there are 
contradictory results concerning the pro-inflammatory effect of 15LOX. In 1995 Shen and co-
worker generated a rabbit overexpressing 15LOX in macrophages, which resulted in a 45% 
decrease in aortic lesion area [211]. 15-LOX-deficient macrophages displayed significantly reduced 
levels of LXA4, which correlated with an enhanced inflammatory gene expression [212]. In 
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addition, a c.-292 C>T polymorphism found in the human 15LOX promoter of macrophages and a 
c.1693 C>T polymorphism (T560M mutation) leading to an inactive enzyme, have been associated 
with CAD, suggesting that 15LOX protects from atherosclerosis [213, 214]. However, these two 
polymorphisms were not associated with myocardial infarction indicating a spatial and temporal 
effect of 15LOX in atherosclerosis[215]. Furthermore, 15LOX is implicated in the formation of the 
anti-inflammatory lipoxins which support the anti-atherogenic role of 15LOX. Recently, LXA4 has 
been shown to be a potent modulator of angiogenesis, which can appear in the development of late 
phase of atherosclerosis [216]. Revascularization of the vessels is associated with lesion formation 
and plaque instability and needs the migration of endothelial cells to organize the formation of the 
vessels. Investigation of the effects of LXA4 analogues in reorganization of endothelial cells 
stimulated with VEGF show an inhibition of endothelial cell migration via the concerted inhibition 
of actin polymerization [217]. LXA4 also inhibits VEGF-stimulated expression of IL-6, TNFα, 
IFNγ and IL-8 secretion in human umbilical vein endothelial cells HUVEC [218]. In addition 10μg 
of ATL-1 analogues in mice reduced the angiogenic phenotype by approximately 50%, indicating 
that lipoxins are important for plaque stability and the onset of cardiovascular disease [219]. Taken 
together, these results indicate that lipoxins have anti-inflammatory and pro-resolution effects on 
atherosclerosis and open new opportunities for treatment of chronic diseases. 
 
1.4.2 ALXR as potential target of atheroslcerosis 
 
Data reported in the GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto 
miocardico) study demonstrate a reduction in sudden death of 45% in patients at risk for myocardial 
infarction for those who were taking omega 3 and aspirin every day (http://www.gissi.org/). Indeed 
in 2002 a meta analysis shows that because of its effective anti-platelet function 75-150mg of 
aspirin taken daily is protective in most patient at increased risk of occlusive vascular events, 
including those with an acute myocardial infarction or ischemic stroke and unstable or stable angina 
[220]. Aspirin blocks COX1 and COX2 by covalently acetylation of a serine residue, thus competing 
with AA for binding at the active site. Thus, the acetylation of COX2 shifts the enzyme from 
producing the pro-inflammatory prostaglandin to the anti-inflammatory 15-epiLXA4 [221] and this 
was also shown with low dose aspirin in humans [61]. Furthermore, newly developed dual COX-5-
LOX inhibitors share the anti-inflammatory effect and gastric safety of COX2 inhibitors, but also 
inhibit COX1-mediated platelet function and 5-LOX-mediated synthesis of gastro-toxic leukotrienes 
[222]. 
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Interestingly for ALXR, a recent study used computational biology approach to predict 
novel GPCR peptide ligands that are cleaved from secreted proteins by convertase proteolysis. 
These ligands were screened for their calcium flux and cAMP activities. The CGEN-855A ligand is 
a novel agonist for ALXR and displays anti-inflammatory activity manifested as a 50% inhibition of 
PMN recruitment to zymosan induced inflamed air pouch. More interesting, CGEN-855A reduced 
36% and 25% of the infarct size in murine and rat models of ischemia-reperfusion-mediated injury 
to the myocardium. The secretion of inflammatory cytokines, including interleukin IL-6, IL-1β, and 
TNFα, were not affected upon incubation of human peripheral blood mononuclear cells with 
CGEN-855A, whereas IL-8 secretion was elevated up to 2-fold upon treatment with the highest 
CGEN-855A dose only [223]. CGEN-855A is therefore an interesting therapeutic drug that binds 
ALXR and could be used to treat acute and chronic inflammation. 
 
 32 
2 RESULTS 
 
2.1 Manuscript 
 
Characterization of the promoter and transcriptional regulation of the ALXR gene in human 
monocytes and macrophages. 
 
Vanessa Waechter(1), Angelika Weber(1), Viola Günther (2), Jacqueline Marti-Jaun(1), Marian Rösinger(1), 
Claudio Gemperle(1), Sophia Wüst(1) and Martin Hersberger(1) 
 
(1) Division of Clinical Chemistry and Biochemistry, University Children’s Hospital Zürich and Center for Integrative 
Human Physiology, University of Zürich, Steinwiesstrasse 75, CH-8032 Zürich, Switzerland. 
 
(2) Institute of Molecular Biology, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich Switzerland. 
 
 
Contribution: 
1. Performed the experiments and generated the figures: 
Figure 1 A/B/C 
Figure 2 A/C; Figure 2 B/D in collaboration with Viola Günther (Group Prof. Schaffner) 
Figure 3 A/B/C in collaboration with the master student Angelika Weber 
Figure 4 A/B/C; Figure 4 D in collaboration with Viola Günther (Group Prof. Schaffner) 
Suplementary data Table S1/S2/S3/S4 
 
2. Wrote the manuscript 
Abstract; Introduction; Experimental procedure, Results, Discussion, Figure legends 
 
 
 
 
 
 
 
 
 
 
 
 
 33 
Characterization of the promoter and the transcriptional 
regulation of the ALXR gene in human monocytes and 
macrophages 
Vanessa Waechter(1), Angelika Weber(1), Viola Günther(2), Jacqueline Marti-Jaun(1), Marian 
Rösinger(1), Claudio Gemperle(1), Sophia Wüst(1) and Martin Hersberger(1) 
(1) Division of Clinical Chemistry and Biochemistry, University Children’s Hospital Zürich and Center 
for Integrative Human Physiology, University of Zürich, Steinwiesstrasse 75, CH-8032 Zürich, 
Switzerland. 
(2) Institute of Molecular Life Sciences, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich 
Switzerland. 
Correspondence and proofs should be sent to: Martin Hersberger, Division of Clinical Chemistry and 
Biochemistry, University Children’s Hospital Zürich, Steinwiesstrasse 75, CH-8032 Zürich, 
Switzerland,Tel. +41-44-266-75-41, Fax. +41-44-266-71-69, E-Mail: martin.hersberger@kispi.uzh.ch 
 
Abstract 
The lipoxin A4 receptor (ALXR) plays an 
important role in host defense and 
inflammation. The receptor binds structurally 
diverse agonistic ligands, including peptides 
and lipid mediators, which mainly regulate 
chemotaxis and activation of leukocytes. 
While the effects of these ligands in leukocytes 
have been investigated, little is known about 
the promoter region of the ALXR gene and 
about its transcriptional regulation in 
leukocytes. We identified two TATA-less 
promoter regions separated by 224 bps which 
drive the expression of the ALXR in 
macrophages. Both promoter regions 
increased transcription in a reporter assay 
and the basal transcription factors, OCT1 and 
SP1, were shown to bind the first and the 
second promoter, respectively, and to 
transactivate transcription. To investigate the 
ALXR mRNA expression in monocytes and 
macrophages, we measured basal expression 
of ALXR mRNA during differentiation of 
monocytes to macrophages and stimulated 
mRNA expression in macrophages. While 
monocytes expressed high levels of ALXR 
mRNA, differentiation into macrophages 
abrogated ALXR expression. Stimulation of 
macrophages with a set of cytokines revealed 
that only IFNγ increased ALXR expression to 
levels similar to the ones detected in 
monocytes. This upregulation by IFNγ is in 
part mediated by IRF1 interacting with an 
IRSE transcription factor binding site located 
in the first promoter region of the ALXR gene. 
These data support the model of ALXR 
playing a role in chemotaxis and activation of 
monocytes, however, they also suggest that its 
role in macrophages is limited to activated 
macrophages stimulated with IFNγ.  
 
 
Introduction 
The lipoxin A4 receptor (ALXR) belongs to the 
class A rhodopsin G protein-coupled receptor 
superfamily (1) and plays a role in chemotaxis 
and activation of phagocytes (2). Several 
structurally diverse agonistic ligands, including 
peptides and lipid mediators have been shown to 
bind to the ALXR. Serum amyloid A (SAA) was 
one of the first chemotactic ligands identified for 
ALXR (3) which led to an increase of IL-8 
secretion in human polymorphonuclear 
neutrophils (PMNs) (4). SAA also induced 
matrix-metalloproteinase 9 (MMP9) generation 
(5) and CCL2 production in a concentration-
dependent manner in human monocytes (6). 
Since the discovery of SAA as a pro-
inflammatory ligand for ALXR, more peptides 
were identified that bind ALXR such as the 
SHAAGtide cleaved from the chemokine 
CCL23, the Helicobacter pylori derived peptide 
Hp-(2-20), the synthetic peptide MMK and the 
beta amyloid peptide (Aβ42)(7-14). These 
peptides do not share apparent homology in 
terms of the primary amino acid sequence but 
induce all pro-inflammatory activation of 
leukocytes through ALXR (2).  
ALXR can also bind anti-inflammatory ligands 
such as LXA4 (15) and annexin-1 (16) which 
leads to reduced PMN recruitment into inflamed 
tissue. LXA4 was shown to inhibit PMN 
migration (17), to induce chemotaxis of 
monocytes (18,19) and to promote the 
nonphlogistic phagocytosis of apoptotic PMNs 
by macrophages (20-22). Similarly, the 
glucocorticoid-induced annexin A1 (ANXA1) 
and its derived peptide Ac2-26, also suppressed 
PMN diapedesis in mouse models of 
inflammation through ALXR (23-26). This anti-
inflammatory effect of the ALXR is further 
supported by findings in two genetically altered 
mouse models. Mice expressing the human 
ALXR showed a significant inhibition of 
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pulmonary inflammation and mice lacking the 
ALXR homologue showed increased emigration 
of leukocytes after ischemia-reperfusion injury 
(27) Thus ALXR might induce anti-
inflammatory actions when pro-resolving 
mediators such as LXA4 and ANXA1 are 
present. 
These opposing effects mediated by the ALXR 
upon binding of pro- and anti-inflammatory 
ligands, suggests that ALXR expression is 
restricted to certain cell types and that its 
expression is tightly regulated. Indeed ALXR 
mRNA is expressed in a limited number of 
primary cells involved in inflammation such as, 
monocytes (18), neutrophils (28), NK cells (29), 
and possibly T-cells (17,30). However, 
regulation of ALXR expression is not well 
understood, with a limited number of regulators 
identified. In synovial fibroblasts treatment with 
the pro-inflammatory TNF-α and IL-1β was 
shown to up-regulate ALXR mRNA expression 
in a time-dependent manner, whereas IL-6 had 
little effect (31). In enterocytes, the pro-
inflammatory cytokine IFNγ and the anti-
inflammatory cytokine IL-13 were shown to be 
the most potent inducers of ALXR expression, 
while IL1-β and LPS only slightly increased the 
expression (32). In mouse macrophages an 
inverse correlation was found between ALXR 
expression and TXA2 signaling (33). In NK cells, 
IL-10 stimulation led to a moderate induction of 
ALXR mRNA (29), and the glucocorticoid 
hormone dexamethasone increased the 
expression of ALXR mRNA in a time- and dose-
dependent manner in PMNs (34,35). These 
findings indicate that ALXR may be regulated by 
pro and anti-inflammatory stimuli and that the 
response to stimulation depends on the cell type 
investigated. 
Since little is known about the promoter region 
of the ALXR and about its transcriptional 
regulation in leukocytes, we set out to define the 
basal promoter of the ALXR gene and to 
investigate its transcriptional regulation in 
human macrophages. We located two TATA-less 
promoter regions in which the basal transcription 
factors OCT1 and SP1 were found to be 
necessary for ALXR transcription, respectively. 
We further show in primary human cells that 
monocytes express high levels of ALXR mRNA, 
while differentiation into macrophages abrogated 
this expression. IFNγ stimulation of 
macrophages rescued ALXR mRNA expression 
in a dose-dependent manner, an effect which was 
at least partially mediated by IRF1 via an IRSE 
element located in the first promoter of ALXR. 
These data support the model that the ALXR 
plays a role in chemotaxis and activation of 
monocytes while its role in macrophages seems 
restricted to activated macrophages stimulated 
with IFNγ. 
 
Experimental procedures 
Material 
The recombinant human cytokines r-interleukin 
13 (IL-13), r-interleukin 1 beta (IL-1β), r-tumor 
necrosis factor alpha (TNFα), r-transforming 
growth factor beta (TGFβ) and r-interferon 
gamma (IFNγ) were purchased from Sigma-
Aldrich (Buchs, Switzerland) 
 
Primary cell purification and cell culture 
Leukocytes from healthy volunteers were 
extracted from 60 ml of heparinized blood or 
buffy coat (Blutspendezentrum Zürich, 
Switzerland) with Histopaque-1077 gradient 
(Sigma-Aldrich). Peripheral blood monocytes 
were purified by capturing with anti-CD14 
antibodies coupled to MACS Microbeads 
(Miltenyi Biotec, Bergisch Glad, Switzerland) 
according to the manufacturer’s instructions. 
Monocytes were allowed to differentiate into 
macrophages for 7 days at 37°C in RPMI-1640 
(Sigma-Aldrich) supplemented with 5 % FCS 
(Bioconcept, Allschwil, Switzerland), 5 % 
human AB serum (Sigma-Aldrich), 1% 
Penicillin/Streptomycin (Invitrogen, Basel, 
Switzerland) and 5 % CO2. Human THP-1 
monocytes (36) were cultured in RPMI-1640 
(Sigma-Aldrich) supplemented with 10 % Fetal 
Calf Serum (FCS) (Bioconcept), 20 mM 
glutamine (Invitrogen) and 5 % CO2.. For 
differentiation into macrophages, cells were 
stimulated for two days with phorbol-12-
myristate-13-acetate (Sigma-Aldrich) (37). 
 
Rapid amplification of cDNA ends (RACE) 
Total RNA was extracted from THP-1 and 
primary macrophages using TRI Reagent 
(Molecular Research Center, Cincinnatti, USA). 
5’RACE was performed using the RLM-RACE 
kit (Ambion, Rotkreuz, Switzerland) according 
to the manufacturer’s instructions. cDNA 
synthesis was performed with random decamers 
and MMLV reverse transcriptase. The first PCR 
reaction was performed with the kit’s 5’race 
outer primer and a reverse primer for ALXR 
(5’CCACCACGATGTGAATTAACT3’), 
designed with the OLIGO 6.0 software 
(Medprobe; www.medprobe.com) on the 
sequence NM001005738.1. The nested PCR was 
carried out with the 5’RACE Inner primer and 
the nested reverse primer for ALXR 
(5’TGGTAATGTGGCCGTGAAAGAAAA3’). 
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The PCR products were loaded on 2 % agarose 
gel and the corresponding bands were eluted 
from the gel and sequenced. 
 
Quantification of ALXR mRNA 
The RT reaction was performed on 1 μg total 
RNA with Superscript III reverse transcriptase 
(Invitrogen) with random primer according to the 
manufacturer’s instructions. Each RT-PCR was 
performed in a total volume of 20 μl on a Light 
Cycler system (Roche Diagnostic, Rotkreuz, 
Switzerland). ALXR mRNA quantification 
included 100 ng cDNA, 4 mM MgCl2, 0.5 mM 
upper primer 
(5’GAAGCACACAGGAAAAGGAG3’), 0.5 
mM lower primer 
(5’GACAAAGGTGACCCCAAG3’) and 1x 
SYBR Green enzyme mix (Roche Diagnostic). 
GAPDH mRNA quantification included 100 ng 
cDNA, 3 mM MgCl2, 0.5 mM upper primer 
(5’CCCATGTTCGTCATGGGTGT3’), 0.5 mM 
lower primer (5’TGGTCATGAGTCCTTCC 
ACGATA3’) and 1x SYBR Green enzyme mix 
(Roche Diagnostic). PCR reactions were 
performed under the following conditions: 
ALXR: preheating of the mixture for 10 min at 
95°C, followed by 45 cycles of denaturation for 
5 sec at 95°C, annealing for 10 sec at 68°C and 
extension for 7 sec at 72°C. GAPDH: preheating 
of the mixture for 10 min at 95°C, followed by 
45 cycles of denaturation for 5 sec at 95°C, 
annealing for 10 sec at 59°C and extension for 6 
sec at 72°C. The primers were designed over 
exon/intron boundaries and amplified PCR 
products were checked for size on agarose gels 
and sequenced. 
 
Generation of promoter constructs 
Promoter constructs were amplified by PCR with 
XhoI upper primers and HindIII lower primers 
(supplementary table S1). Constructs were 
subcloned into the empty pGL3basic vector that 
contains the firefly luciferase gene (Promega, 
Rotkreuz, Switzerland) using the XhoI and 
HindIII restriction enzymes. Point mutations in 
transcription factor binding sites were introduced 
into P1-414 and P1-150 using the QuickChange® 
II XL site directed mutagenesis kit according to 
the manufacturer’s instructions (Stratagene, 
Basel, Switzerland). The primers (Microsynth, 
Balgach, Switzerland) used to mutate P1-414 and 
P2-150, are listed in the supplementary table S2. 
All constructs were sequenced. 
 
Transcription assays 
For each experiment, 6X106 THP-1 cells, 10 μg 
of construct and 0.25 μg of the internal control 
pHRL-SV40 (Promega) were used. 
Electroporation was done under the following 
conditions: 200 V, 950 μF capacitance and ∞ 
resistance. Following electroporation, cells were 
seeded in RPMI-1640 with 10 % FCS and 20 
mM glutamine. Three hours later, cells were 
differentiated into macrophages with PMA for 48 
hrs. For basal transcription assays, cells were 
washed with PBS and harvested. For the IFNγ-
induced transcription assay, cells were stimulated 
another 24 hrs with 50 ng/ml of IFNγ in RPMI-
1640 with 0.5 % FCS, washed with PBS and 
harvested. Harvested cells were lysed in 250 μl 
1x passive lysis buffer and 50 μl were used for 
dual-luciferase reporter assays (Promega). 
 
Preparation of nuclear extracts 
Nuclear extracts were prepared one ice from 
THP-1 macrophages as described in (38). 
Briefly, cells were resuspended in 500 μl of 
Buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 
0,1 mM EDTA. 0,1 mM EGTA, 1 mM DTT, 1 
mM PMSF and protease inhibitors (Complete, 
Roche Diagnostics) and were incubated on a 
rotating wheel for 30 min at 4°C followed by the 
addition of 30 μl of 10% NP-40. After vortexing, 
the nuclei were pelleted by centrifugation for 5 
min at 13000rpm. Nuclei were then resuspended 
in 60 μl of Buffer C (20mM HEPES pH 7.9, 25 
% glycerol, 400 mM NaCl, 1 mM EDTA, 1 mM 
DTT, 1 mM PMSF and protease inhibitors) and 
lysed by shaking for 15min. After centrifugation 
for 5 min at 13000 rpm, nuclear proteins in the 
supernatant were stored at -80°C until use. The 
protein concentration was measured with the M-
TP-Reagent (Beckman Coulter, Nyon, 
Switzerland). 
 
Electromobility shift assay (EMSA) 
2 pmol of double stranded DNA probes 
corresponding to a potential transcription factor 
binding site were end-labelled with 32P-γ-ATP 
(Hartmann Analytic, Germany) by T4 
polynucleotide kinase (Fermentas, Le-Mont-sur-
Lausanne, Switzerland). Sequences of the EMSA 
probes are listed in supplementary table S3. 10 
μg of THP-1 macrophage nuclear extracts and 2 
μg of freshly boiled polydI/dC were added to the 
binding buffer (24 mM HEPES pH 7.9. 24 % 
glycerol, 10 mM NaCl, 100 mM KCl, 10mM 
MgCl2 and 1.2 mM DTT) in a 20 μl binding 
reaction. In the competition experiment 
unlabelled competitor was added in a 50X excess 
to the reaction. The labelled probes were added 
and the reaction was incubated for 20 min at 
room temperature. Samples were analyzed on a 4 
% non-denaturing polyacrylamide gel (0.5x 
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TBE; 4 % acrylamide /bisacrylamide 29:1; 0.075 
% APS, 2.5 % glycerol and TEMED). Gels were 
run at 150 V for 5 hrs, dried and analyzed with 
the scanner FLA-7000 and the software Image 
Gauge (Fujifilm, Basel, Switzerland). For the 
OCT1 probes, reactions were optimized with the 
promega binding buffer (50 mM Tris-HCl pH 
7.5, 250 mM NaCl, 2.5 mM EDTA, 2.5 mM 
DTT, 5 mM MgCl2 and 20 % of glycerol). 
Binding reactions for IRSE used 0.75 μg of 
freshly boiled polydI/dC in binding buffer (20 
mM HEPES pH 7.6; 1 mM EDTA, 1 mM DTT 
and 100 mM KCl). Following addition of the 
probes, the mixture was incubated for 20 min at 
25°C as described in (39). For the supershift 
experiments 4 μg of SP1 antibody (sc-59), 4 μg 
or 10 μg of OCT1 (sc-25399) and 10 μg of IRF1 
(sc-497), ICSBP (sc-13043) or IRF4 (sc-6059) 
were added 1hour prior to the labelled probes at 
4°C. All antibodies were purchased from Santa 
Cruz Biotechnology (Santa Cruz, Heidelberg, 
Germany) 
 
Statistical analysis 
Statistical analysis was performed with StatView 
version 5.0.1 (SAS Institute Inc., Cary, NC). The 
level of ALXR mRNA and the activities of the 
different ALXR promoters in the luciferase 
assays were compared using a two-sided t-test. A 
two-sided p value of <0.05 was considered 
significant. 
 
Results  
The ALXR gene has two promoters leading to 
two distinct transcription start sites 
To define the transcriptional start site of the 
ALXR gene, 5’ rapid amplification of cDNA ends 
was used in primary macrophages. The 
amplification produced two distinct bands of 320 
and 600 bps (fig.1A, lane 2), which represent 
two mRNAs containing both the coding exon 
and the first exon of the ALXR gene but with one 
having a longer version of the first exon. These 
results suggest that the ALXR has two 
transcription start sites (fig.1B) and that ALXR 
transcription may be regulated by two promoters. 
To characterize the transcriptional activity of 
these two potential promoter regions, different 
sized fragments of the two regions were cloned 
upstream of a firefly luciferase reporter gene. As 
shown in fig.1C, all constructs containing 
promoter region P1 directed expression of the 
luciferase, and the shortest construct comprising 
414 bps led to a 4-fold (4.5 ±1.5) increase in 
transcription compared to the empty vector. 
Similarly all constructs containing sequences of 
promoter region P2 directed expression of the 
luciferase with a 4-fold (3.8 ±0.3) increase in 
transcription of the shortest 150 bps promoter 
fragment. These results indicate that one core 
promoter each is located upstream of both 
transcription start sites. 
 
Both ALXR promoters are recognized by basal 
transcription factors 
To characterize basal transcription by the two 
TATA-less promoters P1 and P2 of the ALXR 
gene, we analyzed these regions for transcription 
factor binding sites using the bioinformatic tools 
MatInspector (www.genomatix.de) and Alibaba 
(www.gene-regulation.com). We identified eight 
putative transcription factor binding sites in 
promoter P1 implicated in the formation of the 
transcriptional pre-initiation complex of TATA-
less promoters, namely one PU1, SP1, NFY, 
GATA, SP2 and three OCT1 binding sites. To 
identify the role of these transcription factor 
binding sites on basal transcription, we 
performed site-directed mutagenesis of their core 
binding sites (supplementary table S4). These 
experiments revealed that an OCT1 binding site 
supports the basal transcription activity of 
promoter P1. A single C to A substitution in the 
OCT1 core binding site at position -103 resulted 
in an almost 50 % reduction of luciferase 
expression (47 %±29 %) compared to the wild-
type promoter P1-414 (fig.2A). 
To verify that OCT1 binds to this sequence in 
promoter P1, we performed EMSA analysis with 
THP-1 nuclear extracts. Specific binding of the 
nuclear extracts to this OCT1 oligonucleotide 
was shown (fig.2B lane1) which could be 
competed in the presence of unlabelled wildtype 
but not mutant oligonucleotide (fig.2B lane 2, 
OCT1 and lane 3, mOCT1). The presence of the 
A to C mutation at position -103 also 
dramatically reduced binding of nuclear proteins 
(fig.2B lane 5). To show that OCT1 is part of the 
protein complex binding to the OCT1 
oligonucleotide, nuclear extracts were co-
incubated with an OCT1 antibody. The observed 
supershift demonstrates that OCT1 is binding to 
the OCT1 transcription factor binding site in 
promoter P1 (fig.2B lane 4). This finding is 
further supported by the similar supershift 
observed with the designed OCT1 
oligonucleotide used as a positive control (fig.2B 
lane 6). 
We also identified two putative basal 
transcription factor binding sites in promoter P2, 
namely a NFY and SP1 binding site. Mutations 
in the core binding site of both NFY and SP1 
(supplementary table S4) resulted in a 83 % (±3 
%) and 91 % (±3 %) reduction of promoter 
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activity compared to the wild-type promoter P2-
150, respectively (fig.2C). To confirm the 
binding of NFY and SP1 to promoter P2, we 
again performed EMSA analysis with THP-1 
nuclear extracts. Direct binding of nuclear 
proteins to the SP1 and NFY oligonucleotides 
was confirmed (fig.2D lane 1 and lane 6) and a 
decrease in binding was observed for both 
transcription factor binding sites when the core 
binding site was mutated (fig.2D lane 9 and 10). 
Binding to the SP1 oligonucleotide could be 
competed with unlabelled SP1 oligonucleotide 
(fig.2D lane 2, SP1) but not with mutant 
unlabelled SP1 oligonucleotide (fig.2D lane 4, 
mSP1). However, the NFY oligonucleotide also 
competed with the SP1 oligonucleotide and vice 
versa (fig.2D lane 3, NFY and 7, SP1), 
suggesting that these overlapping transcription 
factor binding sites are recognized by the same 
protein complex. Co-incubation of the nuclear 
extracts with a SP1 antibody supported this 
finding, showing the identical supershift for both 
SP1 and NFY oligonucleotides (fig.2D lane 5 
and 8 respectively), while no supershift was 
observed with an antibody against NFY (data not 
shown). Taken together, these results indicate 
that SP1 is part of the complex binding the core 
promoter region P2 to activate basal 
transcription. 
 
ALXR mRNAs is downregulated during 
monocyte differentiation and upregulated in 
macrophages by IFNγ 
In an effort to understand the role of ALXR in 
macrophages during inflammation we 
investigated the level of ALXR mRNA during 
the differentiation of primary monocytes to 
macrophages. Our results show that monocytes 
but not 7 days old macrophages express ALXR 
mRNA (fig.3A). These results indicate that 
macrophages need external stimuli to produce 
ALXR. Such an upregulation of the ALXR 
mRNAs was shown for different types of 
cytokines, however, whether this is true in 
macrophages has not been investigated. To 
answer this question, primary macrophages were 
stimulated with several cytokines known to be 
secreted during inflammation (fig.3B). 50 ng/ml 
of the pro-inflammatory cytokine IFNγ resulted 
in an 80-fold increase in the expression of ALXR 
mRNA compared to the non-stimulated cells, 
whereas stimulation with the other pro- and anti-
inflammatory cytokines showed no alteration of 
ALXR mRNA expression. Thus IFNγ-
stimulation led to the rescue of mRNA 
production lost during the differentiation to 
macrophages (data not shown). In addition, 
increasing concentrations of INFγ showed that 
the effect on ALXR mRNA was dose-dependent 
(fig.3C). Taken together these results indicate 
that ALXR is tightly regulated and that IFNγ 
recruits the transcriptional machinery to increase 
promoter activity and thus ALXR mRNA 
expression. 
 
INFγ increases transcriptional activity of the first 
promoter via an IRSE element 
To locate the IFNγ response element in the ALXR 
promoter, THP-1 macrophages were subjected to 
24 hrs stimulation with IFNγ after 
electroporation of the different constructs of 
promoters P1 and P2. As seen in fig.4A IFNγ-
stimulation resulted in a 1.5-fold (±0.6) increase 
in luciferase expression for the first promoter P1 
compared to non-stimulated cells, whereas IFNγ 
had no stimulatory effect on the second promoter 
P2. Theses results suggest that P1 contains the 
transcriptional elements which promote the IFNγ 
dependent stimulation of the ALXR gene. 
MatInspector located two putative binding sites 
for IRF4 and IRF7 within this region. These 
transcription factors have already been shown to 
induce transcription upon stimulation with 
interferons (40,41). To investigate whether one 
or both of these transcription factor binding sites 
are necessary for the IFNγ response of the ALXR 
gene, their core binding sites were mutated on 
the shortest P1-414 luciferase-construct 
(supplementary table S4). Site-directed 
mutagenesis of the core binding site for IRF4 
resulted in a 48 % decrease in basal 
transcriptional activity compared to the wildtype 
construct, while site-directed mutagenesis of 
IRF7 did not alter the promoter activity (fig.4B). 
In addition, when cells were stimulated with 
IFNγ, the construct containing the mutant IRF4 
binding site showed decreased transcription even 
compared to non-stimulated cells (p=0.038) 
(fig.4C). All together these results indicate that 
the transcription factor binding site for IRF4 is 
important for basal and IFNγ-induced 
transcription of ALXR. EMSA confirmed binding 
of proteins from nuclear extracts from non-
stimulated (fig.4D, lane1) and even more from 
IFNγ-stimulated macrophages (fig.4D, lane2) to 
the IRF4 oligonucleotide. Interestingly, 
stimulation of macrophages with IFNγ changed 
the size of DNA-protein complexes indicating 
differential regulation for basal and induced 
transcription. This binding could be competed 
with unlabelled IRF4 oligonucleotide (fig.4D, 
lane 3, IRF4) but less so with a mutant version 
(fig.4D, lane 4, mIRF4), supporting a role for 
this transcription factor binding site in IFNγ 
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stimulation. However, incubation of the IRF4 
oligonucleotide with nuclear extracts in the 
presence of an IRF4 antibody did not result in a 
supershift of the protein-DNA complex (fig.4D, 
lane 7), arguing against an involvement of IRF4 
in IFNγ-stimulation of the ALXR gene. Since 
members of the IRF family of transcription 
factors bind to interferon-stimulated response 
elements (IRSE) (42) and the IRF4 site also 
matches this IRSE consensus sequence, we 
probed the protein-DNA complexes with several 
antibodies against transcription factors of the IRF 
family. As can be seen in figure 4D, only 
incubation with the IRF1 antibody resulted in a 
supershift of the protein-DNA complexes (lane 
10). All together, these results indicate that IFNγ 
stimulates the transcription of the ALXR gene via 
IRF1 binding to the ISRE element located in the 
first promoter P1. 
 
Discussion 
We identified and characterized two promoter 
regions in the ALXR gene separated by 224 bps 
which drive the ALXR mRNA expression in 
monocytes and macrophages. We also show that 
transcription of the ALXR gene from these 
promoters decreases during differentiation of 
primary human monocytes to macrophages and 
that the low transcription in macrophages can be 
rescued by IFNγ-stimulation. On the molecular 
level, we have identified that the transcription 
factors OCT1 and SP1 are involved in the 
initiation of transcription in the TATA-less 
promoter 1 and 2 of the ALXR gene, respectively. 
We have further located the IFNγ response 
element to promoter 1 and have shown that for 
IFNγ-stimulation of ALXR mRNA transcription 
the transcription factor IRF1 binds an IRES 
transcription factor binding site in promoter 1. 
Two distinct promoters are located in the ALXR 
gene which result in alternative 5’UTRs of the 
ALXR mRNA in macrophages. Both promoters 
lack a TATA box at position -25 but have basal 
transcription factor binding sites present, which 
were previously shown to initiate transcription of 
TATA-less promoters. The promoter P1 contains 
an OCT1 binding site which has previously been 
shown to play a critical role in the pre-initiation 
complex recruitment of promoters that lack 
TATA boxes. For instance, OCT1 was able to 
replace TBP via its interaction with the general 
transcription factor TFIIB for the transcription of 
the lipoprotein lipase gene (43). Similarly, the 
promoter P2 contains a basal transcription factor 
binding site for SP1, which is known to bind 
CpG islands and also to drive gene transcription 
of TATA-less promoters (44). Both of these 
promoters seem to initiate basal transcription of 
the ALXR gene in monocytes and less so in 
macrophages but only the first promoter P1 has 
the necessary transcription factor binding sites 
for IFNγ-stimulation. 
This first promoter P1 is responsive to IFNγ-
stimulation and contains an IRSE element 
recognized by the transcription factor IRF1. The 
signalling pathways of IFNγ-stimulation involves 
either the activation of the JAK/STAT pathway 
or an increase in transcription of Interferon 
Regulatory Factors (IRF) (45), which both leads 
to enhanced transcription of downstream genes. 
Here we show that IRF1 supports the increased 
ALXR expression through binding to an IRSE 
binding site (46) in the first promoter of the 
ALXR gene. IRF1 is one of the highest induced 
members of the IRF family and was shown to be 
highly upregulated by IFNγ in THP-1 monocytes 
(47). This resulted in a strong increase in IRF1 
binding to the IRSE element in the β2-
microglobulin promoter (47) similar to the 
binding shown in our EMSA experiment with the 
IRSE element in the first promoter P1 of the 
ALXR gene. 
Our finding that the ALXR is expressed to high 
levels in monocytes supports the role of the 
ALXR in chemotaxis, while the observed 
downregulation of the mRNA during 
differentiation limits its role in macrophages. 
The ALXR plays a role in chemotaxis of 
monocytes during inflammation, which results 
from a gradient of pro-inflammatory or anti-
inflammatory ligands. Depending on the ligand 
and the environment of the invaded tissue, the 
monocyte may then differentiate into either a 
pro-inflammatory M1 or a non-phlogistic M2 
macrophage. For example, SAA accelerates 
inflammation through the ALXR and has been 
shown to stimulate monocytes to produce the 
pro-inflammatory chemokine CCL2 (6) and 
TNFα (48). In contrast, treatment of monocytes 
with the ALXR ligand LXA4 was shown to 
recruit monocytes to the site of inflammation 
without leading to cytotoxicity and superoxide 
generation (18,49). These monocytes 
differentiated into pro-resolving M2 
macrophages, which take up apoptotic cells from 
the inflamed tissue and support tissue 
homeostasis. Therefore, high expression of 
ALXR in monocytes may reflect its role in 
signalling chemotactic stimuli but also in 
signalling pro- or anti-inflammatory effects 
depending on the environment. 
During differentiation of monocytes to 
macrophages expression of the ALXR gene 
decreases and only stimulation of macrophages 
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with IFNγ rescues ALXR transcription, while 
other pro- and anti-inflammatory cytokines had 
no effect on ALXR mRNA levels. These data 
suggest that only the subset of M1 macrophages 
stimulated with IFNγ will respond to ALXR 
ligands, while other classes of resident 
macrophages will not. IFNγ is an endogenous 
mediator of immunity and inflammation and 
plays a complex and central role in the resistance 
of the mammalian host to pathogens. IFNγ 
stimulation of monocytes and macrophages leads 
to the development of classical activated M1 
macrophages, which display enhanced endocytic 
functions and have the ability to kill intracellular 
pathogens (50,51). Thus it is likely that other 
pro-inflammatory mediators like the ALXR 
ligand SAA are present in concert with IFNγ, 
suggesting that the induced expression of ALXR 
in these M1 macrophages will accelerate 
inflammation. Nevertheless, upregulation of 
ALXR in macrophages by IFNγ may also lead to 
the resolution of inflammation and tissue repair, 
when the anti-inflammatory ligands annexin1 or 
LXA4 rise in concentration during the resolution 
phase of inflammation. 
While cell surface expression of the ALXR on 
monocytes has recently been demonstrated (52), 
data on cell surface expression of ALXR on 
macrophages are lacking. We were able to detect 
ALXR expression on the cell surface in 
monocytes by FACS analysis and could confirm 
its absence on macrophages. However, we could 
not detect ALXR cell surface expression in 
macrophages stimulated with IFNγ. This may be 
due to technical problems of detaching 
macrophages from cell culture dishes, although 
we could detect the presence of other cell surface 
receptors on macrophages (data not shown). 
Western blot analysis was also not successful 
because none of several commercial antibodies 
was specific for ALXR. Another explanation for 
this discrepancy of mRNA and cell surface 
expression of the protein may be that post-
transcriptional mechanisms regulate ALXR 
abundance on the cell surface. Our data indicate 
that IFNγ-stimulated transcription of the ALXR 
gene leads to the mRNA containing the longer 
5’UTR because only the first promoter contains 
the IRES element and is responsive to IFNγ-
stimulation. The 5’UTRs are known to contain 
regulatory motifs (53,54) that have an effect on 
translational efficiency, like target sequences for 
MicroRNAs (55), internal ribosome entry sites 
(56), hairpin secondary structures (57), upstream 
translation initiation codons (uAUG) and 
upstream open reading frames (uORF). In this 
line, the longer 5’UTR of the ALXR mRNA 
derived from promoter P1 contains an uORF 
which may lead to a poor translation of this 
ALXR mRNA (58). This is supported by recent 
studies which revealed that the presence of an 
uORFs in human genes results in a 30-80% 
reduction in protein expression or even in a full 
block of translation (53,59-61). Hence, IFNγ 
stimulation of macrophages may result in ALXR 
mRNA containing the uORF which may not be 
efficiently translated and therefore not support 
membrane expression of the receptor. 
In summary, we have characterized the 
regulatory sequences and some components of 
the transcriptional machinery that drives the 
expression of the ALXR gene in monocytes and 
macrophages. Our data also suggest that the 
ALXR mRNA is expressed in monocytes but 
only in a limited set of macrophages stimulated 
with IFNγ. This supports the current model that 
the ALXR is a chemotactic receptor in 
monocytes, however, limits its role in 
macrophages to the IFNγ stimulated pro-
inflammatory macrophages. 
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Legends 
Figure 1: Location of the ALXR promoters in macrophages. A: PCR products are visualized on a 2 
% agarose gel after nested 5’RACE. Lane 1: Gene specific nested amplification (forward nested gene 
specific primer and reverse gene specific inner primer). Lane 2: Race specific nested amplification 
(forward 5’RACE adapter nested inner primer and reverse gene specific inner primer). B: Genomic 
sequence including the ALXR promoters with the two transcription start sites indicated as +1. 
Transcription factor binding sites identified for AXLR transcription are underlined. C: Promoter 
constructs were cloned into a pGL3 basic luciferase vector and are referenced as numbers in base pairs 
relative to +1 for the first promoter P1 and for the second promoter P2. Human THP-1 monocytes 
were transfected with the constructs, differentiated into macrophages and luciferase activities were 
measured 48 hrs after transfection. Firefly luciferase activities were normalized to Renilla luciferase 
activities and all experiments were done in triplicates. Bars indicate the means of three independent 
experiments with three plasmid preparations. Values represent fold induction over the empty vector 
pGL3b and the error bars display standard deviation (± SD). *p<0.05; **p<0.01. 
 
Figure 2: Identification of basal transcription factor binding sites in the ALXR promoter region. 
Putative basal transcription factor binding sites for P1-414 and P2-150 were identified with the 
softwares Genomatix and Alibaba. A. and C: Individual transcription factor binding sites were 
mutated in P1-414 (A) and P2-150 (C). For mutations introduced see supplementary table S4. Human 
THP-1 monocytes were transfected with the constructs, differentiated into macrophages and luciferase 
activities were measured 48 hrs after transfection. Firefly luciferase activities were normalized to 
Renilla luciferase activities and all experiments were done in triplicate. Bars indicate the means of 
three independent experiments with three plasmid preparations. Values represent fold induction over 
P1-414 and P2-150, respectively. B. Electrophoretic mobility shift assays for the potential OCT1 
binding site with nuclear extracts from THP-1 macrophages. The DNA-protein complex with OCT1 
oligonucleotides was analyzed by gel electrophoresis and visualized by autoradiography (lane 1). For 
competition assays, the nuclear extracts were preincubated with excess of unlabeled OCT1 or mutant 
OCT1 oligonucleotides (OCT1: lane 2; mOCT1: lane 3). For supershift analysis, the nuclear extracts 
were preincubated with an OCT1 antibody (lane 4). The nuclear proteins were incubated with the 
mutant OCT1 oligonucleotide to test direct binding (lane 5). A control of supershift was done with 
OCT1 antibody and a designed OCT1 oligonucleotide (lane 6). D. Electrophoretic mobility shift assay 
for SP1 and NFY. DNA-protein complexes with SP1 and NFY oligonucleotides were visualized by 
autoradiography (lane1 and lane 6, respectively). Competition assays were performed with three 
competitors for SP1: SP1 (lane 2), NFY (lane 3) and mutant SP1 (mSP1: lane 4). One competitor was 
used for NFY: SP1 (lane 7). SP1 antibody was used for supershift assays with the SP1 and NFY 
oligonucleotides (lane 5 and lane 8). The nuclear extracts were incubated with the mutant SP1 (mSP1: 
lane 9) and the mutant NFY oligonucleotides (mNFY: lane 10) to see abrogated direct binding. 
Sequences of the different oligonucleotides can be found in the supplementary table S3. Error bars 
display standard deviation (± SD) *p<0.05; **p<0.01. Ab: supershift with antibody. 
 
Figure 3: Regulation of ALXR mRNA expression. ALXR mRNA was determined by real-time RT-
PCR in primary monocytes and macrophages. A: Monocytes extracted from buffy coat (day 0) were 
allowed to differentiate into macrophages for 1, 3, 6, and 7days. ALXR mRNA values were 
normalized to GAPDH mRNA levels and results represent fold induction compared to monocyte 
expression levels at day 0. B: Total RNA was extracted from 7 days old macrophages stimulated for 
24 hrs with IL-13, IL-1β, TNFα, TGFβ, and IFNγ. Values represent fold induction compared to the 
non-stimulated cells. C: Ratio of ALXR/GAPDH expression levels of cells stimulated with different 
concentrations of IFNγ (-: no stimulation; 10 ng/ml; 25 ng/ml; 50 ng/ml). Error bars display standard 
deviation (± SD); n=3; *p<0.05; **p<0.01. 
 
Figure 4: Location of the IFNγ response element. A: THP-1 monocytes were transfected with the 
different constructs of promoter P1 and P2 and differentiated into macrophages for 2 days. Cells were 
further stimulated with IFNγ for 24 hrs and luciferase activities were measured and normalised to the 
activity of the Renilla luciferase. Bars indicate the means of three independent experiments with three 
plasmid preparations. Values represent fold induction of the respective construct compared to non-
stimulated cells. B and C: Site-directed mutagenesis of the putative interferon response elements IRF4 
and IRF7 in construct P1-414 (for mutations see supplementary table S4). Luciferase activity was 
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measured 48 hrs after transfection (B) and following 24 hrs stimulation with IFNγ (C). Bars indicate 
the means of three independent experiments with three plasmid preparations. Values represent fold 
induction over the P1-414 construct (B) or over the respective construct in non-stimulated cells. D: 
EMSA for IRF4 with the nuclear extracts from THP-1 macrophages (lane 1) and THP-1 macrophages 
stimulated for 24 hrs with IFNγ (lane 2). For competition assays, the stimulated nuclear extracts were 
preincubated with excess of unlabeled IRF4 (lane 3) or mutant IRF4 oligonucleotides (mIRF4: lane 4). 
As the binding site overlaps with a putative OCT1 transcription factor binding site, nuclear extracts 
from non-stimulated cells were preincubated with an excess of unlabelled designed OCT1 
oligonucleotide (lane 5). The nuclear extracts from stimulated macrophages were incubated with the 
mutant IRF4 oligonucleotide to test direct binding (lane 6). For supershift assays IRF4, ISBCP, OCT1 
and IRF1 antibodies were preincubated with the IRF4 oligonucleotide (lane 7, 8, 9 and 10). Sequences 
of oligonucleotides can be found in the supplementary table S3. Error bars display standard deviation 
(± SD). *p<0.05; **p<0.01. Ab: supershift with antibody. 
 
 Manuscript page XI 
Figure 1: 
 
 Manuscript page XII 
Figure2: 
 
 
 Manuscript page XIII 
Figure 3: 
 
 Manuscript page XIV 
Figure 4: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Manuscript page XV 
Table S1: Primers sequences used for plasmid constructs. 
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Table S2: Sequences of primers used for site-directed mutagenesis. 
 
 
 
(a). Position relative to the transcriptional start site of the respective promoter P1 or P2 
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Table S3: Oligonucleotides used for electromobility shift assay. 
 
 
 
(a). Position relative to the transcriptional start site of the respective promoter P1 or P2 
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Table S4: Putative transcription factor binding site of the ALXR promoter regions. 
 
 
 
(a). Position relative to the transcriptional start site of the respective promoter P1 or P2 
(b). Sequence used for site-directed mutagenesis; in red nucleotides important for transcription factor 
binding, in capital their core binding site and in blue nucleotide change used for site-directed 
mutagenesis. 
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a b s t r a c t
The12/15-lipoxygenaseplaysa janus-role in inflammationwithpro-inflammatoryandanti-inflammatory
effects in cell systems and even opposite effects on atherosclerosis in two different animal species.
Screening of the human 15-lipoxygenase (ALOX15) gene detected a polymorphic C to T substitution at
position c.−292, which led to three times higher ALOX15 activity in macrophages and showed a trend
to be atheroprotective in a small case–control study for coronary artery disease (CAD). A second poly-
morphism at position c.1693C>T leading to an T560M exchange and an inactive enzyme was recently
associatedwith increasedCAD.Wenowinvestigatedwhether thesepolymorphismsora certainhaplotype
of ALOX15 are associated with myocardial infarction (MI) in a case–control subset from the population-
based MONIKA/KORA cohort S3. Six polymorphisms in ALOX15 were analyzed in 2629 participants to
cover allmajor haplotypeswith a frequency higher than 1% in the Caucasian population. None of the poly-
morphism was associated with MI but a rare ALOX15 haplotype showed a significant protective effect onLOX15
LOX12
nflammation
therosclerosis
yocardial infarction
enetics
the risk forMI (p=0.03). However, none of the polymorphisms or haplotypeswas associatedwith CRP lev-
els. These data suggest that ALOX15 may play a less prominent role during later stages of atherosclerosis
involving atherothrombotic mechanisms than eventually during early plaque development.
© 2008 Elsevier Ireland Ltd. All rights reserved.aplotype
olymorphism
. Introduction
A wealth of information emerged about the involvement of
he 12/15-lipoxygenases in atherosclerosis with several of its
echanisms ascribed to pro-atherosclerotic pathways (for review
ee Ref. [1]). The reticulocyte-type 12/15-lipoxygenase directly
xygenates linoleic acid esters on LDL particles leading to the for-
ation of oxLDL and to foam cell formation [2–6]. On the other
∗ Corresponding author. Tel.: +41 44 266 7541; fax: +41 44 266 7169.
E-mail address: martin.hersberger@kispi.uzh.ch (M. Hersberger).
021-9150/$ – see front matter © 2008 Elsevier Ireland Ltd. All rights reserved.
oi:10.1016/j.atherosclerosis.2008.11.017hand, there is compelling evidence for an anti-inflammatory and
anti-atherosclerotic effect of the 12/15-lipoxygenases through the
generation of lipid mediators involved in the resolution of inflam-
mation [1]. The12/15-lipoxygenase is involved in themetabolismof
at least four classes of such pro-resolution lipid mediators, includ-
ing the production of 15-HETE and the lipoxins from arachidonic
acid [7], of 13-HODE from linoleic acid [8,9] and of the resolvins
from DHA [10].
Animal models of atherosclerosis did not solve the question of
whether the 12/15-lipoxygenase activity is pro- or anti-atherogenic
because two different animal models showed contrasting results
[11–15]. The discrepancies observed between different animal
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odels have been explained by the different positional selectivi-
ies of themammalian 12- and 15-lipoxygenase iso-enzymeswhich
xidize arachidonic acid at the carbon atoms 12 and 15 and which
ave different expression patterns [1].
In light of these contradicting reports and the equivocal results
n two animal models of atherosclerosis [11–15], it will be essen-
ial to dissect the effect of the human reticulocyte 15-lipoxygenase
ALOX15) on human atherosclerosis for cardiovascular risk assess-
ent in humans. Since functionally relevant polymorphisms in
he ALOX15 gene could elucidate whether altered ALOX15 activ-
ty does influence disease progression in humans, we recently
creened the ALOX15 gene for polymorphisms and detected 11
ariations of which five defined all major haplotypes with frequen-
ies >0.01 [16]. One of the polymorphisms, a C to T substitution
t position c.−292 in the ALOX15 promoter, created a novel tran-
cription factor binding site for the myeloid specific transcription
actor SPI1 [16]. Binding of SPI1 to the c.−292T promoter increased
LOX15 transcription and activity in macrophages from heterozy-
ous c.−292C>T carriers [16,17]. This functional polymorphism
howed a trend to be atheroprotective in a small case–control study
or coronary artery disease (CAD) [17]. In addition, a recent study
howed evidence for another rare polymorphism in ALOX15 to be
ssociated with CAD in two independent samples [18]. This T560M
LOX15 polymorphism with a minor allele frequency of 1.2% in
aucasians was shown to have 20 times reduced enzyme activity
nd was associated with an increased risk for CAD. Hence, both
tudies investigating the association with either an activating or
n inactivating polymorphism in human ALOX15 suggest that the
hysiological ALOX15 expression does not accelerate atherosclero-
is but protects from atherosclerosis.
In this study,we investigatedwhether anyof the functional poly-
orphisms or a haplotype of the ALOX15 gene is associated with
yocardial infarction (MI) in the MONIKA/KORA cohort S3 and in
he KORA B study, a large case–control study including 518 cases
nd 2111 controls.
. Materials and methods
.1. Study population
Cases were derived from the KORA B study on patients with
yocardial infarction (MI). In 1996, a total of 589 patients with
istory of sporadic MI prior to the age of 60 years were identified
hrough theAugsburg, Germany,MONIKAMI register and invited to
he study centre. The diagnosis of MI was established according to
he MONIKA diagnostic criteria. MI patients were studied by phys-
cal examination, blood testing, echocardiography, and a detailed
tandardized interview. Controlsweredefinedas studyparticipants
ithout MI from the population-based KORA study S3, which has
een conducted during the years 1994/1995 in the region of Augs-
urg. Study participants were selected based on local registries and
nvited to undergo medical examination in the KORA study centre
19].
.2. Genetic analysis
Genotyping was performed as previously described [20,21].
riefly, genomic DNA was extracted from whole blood by stan-
ard salting-out method. High quality DNA for genotyping
as obtained from 518 MI cases and 2111 controls. Genotyp-
ng of SNPs c.−635A>G (rs2255888), c.−186G>C (rs2664593),
.337+8C>T (rs11078528), c.1693C>T (rs34210653, T560M) and
.2076+200C>T (rs11568131) in ALOX15was done at theGenotyp-
ngUnit of theGeneDiscoveryCoreFacility at the InnsbruckMedical
niversity, Austria, using a 5′ nuclease allelic discrimination (Taq-
an) assay in all subjects with sufficient amount and quality ofrosis 205 (2009) 192–196 193
DNA [21]. The MassArray system (Sequenom, San Diego, CA) was
used for genotyping of c.−292C>T (rs11568070) whereby a base-
specific extension reaction was performed with Thermosequenase
(Amersham, Piscataway, NJ) and this reaction was dispensed onto
a 384-format Spectro-Chip (Sequenom) [20]. A matrix-assisted
laser desorption ionization time-of-flight mass (MALDI-TOF) spec-
trometer, model Bruker Autoflex (Sequenom), was used for data
acquisition. Genotyping calls were made in real time with MassAr-
ray RT software (Sequenom). Calling rates were above 95% for all
SNPs anddid not differ between cases and controls for an individual
assay.
2.3. Statistical analysis
Differences in study characteristics were tested either through
non-parametric Mann–Whitney U tests for continuous variables
and 2 tests or Fisher’s exact test for categorical variables. SNP
association analysis was performed under the assumption of an
additive genetic effect model. Association with MI was analyzed
through logistic regression models, association with CRP plasma
levels through linear regression (on the log scale for CRP). All associ-
ation analyses were adjusted for age and sex. Haplotype estimation
was performed using “haplo.em” from R library “haplo.stats” [22]
stratified by case–control status and only for individuals with com-
plete genotype information in all SNPs. A likelihood ratio test to
test for differences in haplotype frequency estimates between cases
and controls was applied. For haplotype analysis, the expected
number of copies of all haplotypes with frequency ≥1% were cal-
culated and coded as covariates. Haplotypes with probabilities
<1% were collected into a group of rare haplotypes. All hap-
lotype variables (including the group of rare haplotypes) were
modelled against the group of subjects with two copies of the
most frequent haplotypes (reference). All haplotype analyses were
adjusted for sex and age alone or additionally for waist, HDL-
C and hypertension. Significance was defined for p-values below
0.05.
3. Results
To investigate the influence of ALOX15 on atherosclerosis, we
analyzed the association of six polymorphisms including the func-
tional polymorphisms c.−292C>T and T560M in ALOX15 with MI
in the MONIKA/KORA case–control sub-study including 518 Cau-
casian cases and 2111 healthy controls. The characteristics of the
controls and cases are shown in Table 1. No significant associa-
tion between the detected genetic variants in the ALOX15 gene and
MI was observed (Table 2) but the rare functional polymorphism
T560M leading to reduced ALOX15 enzymatic activity showed a
trend to increase the risk of MI (OR 1.7, CI: 0.96–3.01, p=0.06). A
similar trend for an association was observed when the analysis of
the T560M polymorphism was restricted to men only (OR=1.9, CI:
1.0–3.7, p=0.05).
Haplotype analysis of the ALOX15 gene in the MONIKA/KORA
cohort revealed nine previously defined haplotypes (Table 3) with
similar frequencies to the ones found in a Swiss study population
[16]. Since theT560Mpolymorphismwasonlyobserved in rarehap-
lotypes with a frequency below 1% in the entire population and no
further contribution tohaplotypeassociationanalysiswasexpected
from this SNP, we excluded this SNP from haplotype estimation,
in order to increase the number of individuals with comprehen-
sive genotype information. Logistic regression analysis adjusted for
age and sex showed a significant association of haplotypes 4 and 8
with MI (phaplo.4 = 0.02, phaplo.8 = 0.03). After the additional adjust-
ment forwaist, hypertension, andHDL-Conlyhaplotype4remained
significantly associated with MI while the association for haplo-
type 8 became borderline significant (phaplo.4 = 0.03, phaplo.8 = 0.05,
194 M. Hersberger et al. / Atherosclerosis 205 (2009) 192–196
Table 1
Characteristics of controls and cases.
Controls (n=2111) Cases (n=518) p-Value
Age (years) 56.0 (51.0; 62.0)a 58.0 (54.0; 61.0) 0.0002
Male (%) 49.3 87.6 <10−20
Hx of diabetes (%)b 6.3 16.5 <10−13
Hx of hypertension (%)b 50.7 64.5 1.8×10−8
Lipid lowering medication 4.4 41.7 <10−20
Smoking 2.2×10−16
Non-smokers 50.9 12.5
Ex-smokers 29.4 65.1
Current smokers 19.8 22.0
Waist (cm) 93.0 (84.0; 100.9) 101.0 (94.5; 108.0) <10−20
Hip (cm) 104.0 (99.5; 109.0) 102.0 (98.0; 107.0) 7.3×10−7
Alcohol (g/day) 5.7 (0; 24.6) 8.7 (0; 25.7) 0.1720
Cholesterol (mg/dl) 238.6 (212.1; 266.7) 235.6 (206.8; 268.7) 0.1541
HDL-C (mg/dl) 51.0 (42.0; 62.4) 48.0 (40.5; 58.6) 4.0×10−5
LDL-C (mg/dl) 148.0 (122.9; 176.0) 139.7 (112.7; 168.4) 8.3×10−6
Total C/HDL-C ratio 4.7 (3.7; 5.8) 4.9 (4.0; 5.8) 0.0120
CRP (mg/l) 1.6 (0.8; 3.2) 2.2 (1.1; 3.9) 9.4×10−9
a Median (interquartile range).
b Hx of [. . .] = history of [. . .].
Table 2
Exact logistic regression models predicting case-status (MI).a
Variation MAF (%) genotypes Odds-ratioa 95% CI p-Value
Controls (n=2111) Cases (n=518)
c.−635A>G 25.3 23.4 0.96 0.81–1.14 0.63
rs2255888 1176/794/135 308/174/34
c.−292C>T 1.7 1.7 1.04 0.58–1.76 0.89
rs11568070 2038/69/1 501/16/1
c.−186G>C 22.1 21.4 0.98 0.82–1.18 0.84
rs2664593 1240/700/101 310/155/28
c.337+8C>T 27.3 29.0 1.07 0.91–1.26 0.41
rs11078528 1112/841/154 264/205/47
c.1693C>T 1.3 2.0 1.73 0.43–2.30 0.06
rs34210653 1976/51/1 458/19/0
c
r 3
d
b
(
i
T
P
H
1
1
8
5
1
4
1
1
9
R.2076+200C>T 16.5 14.5
s11568131 1417/546/60 359/116/1
a Age and sex adjusted using an additive genetic effect model.
ata not shown). However, no overall significant difference
etween haplotype frequencies in cases and controls was found
p=0.23).
To explore whether these haplotypes modulate the anti-
nflammatory role of ALOX15, we performed linear regression
able 3
redicted haplotypes and their frequencies in the studya and results from logistic regress
aplotype Allelesa Frequency in
Controls (n=1997) Cases (
4 ACGTC 0.254 0.278
0 ACGCC 0.243 0.254
ACCCC 0.176 0.175
GCGCT 0.119 0.112
1 GCGCC 0.111 0.094
ACGCT 0.022 0.012
ACCCT 0.019 0.013
2 ATGCC 0.016 0.016
GCCCC 0.016 0.009
arec 0.013 0.016
a Haplotypes formed by the alleles of the ALOX15 polymorphisms c.−635A>G, c.−292C
b Adjusted for age and sex.
c Haplotypes with frequencies <0.01 were pooled in a group as rare haplotypes.0.88 0.71–1.08 0.21
analyses to investigate the influence of the ALOX15 haplotypes on
CRP levels. No haplotype and no individual polymorphism were
associated with CRP levels without or with adjustment for case sta-
tus, age, sex, waist, hypertension, lipid lowering drugs, and HDL-C
(data not shown).
ion models predicting case-status (MI).b
OR 95% CI p-Value
n=486)
– – –
1.002 0.811–1.237 0.98
1.305 1.027–1.656 0.03
1.205 0.920–1.571 0.17
1.080 0.805–1.442 0.60
0.408 0.180–0.826 0.02
0.705 0.328–1.389 0.34
1.078 0.581–1.903 0.80
0 0–0 0.96
5.999 2.884–12.635 <0.001
>T, c.−186G>C, c.337+8C>T, c.2076+200C>T. Rare alleles are printed in bold.
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. Discussion
ALOX15 was previously shown to have contrary effects on
therosclerosis in different animal models, which complicated the
nterpretation of the role of the enzyme in human atherosclerosis.
e and others previously identified two rare functional polymor-
hisms in ALOX15, which led to increased (c.−292C>T) [16] and
educed (T560M) [18] enzyme activity, respectively. While the
ctivating c.−292C>T polymorphism showed a trend towards an
theroprotective effect in a case–control study for CAD, the inac-
ivating T560M polymorphism was associated with a significantly
ncreased risk for CAD, indicating that ALOX15 is anti-inflammatory
nd anti-atherogenic in humans [17,18]. In the present study, we
nvestigated for the first time the role of ALOX15 on the emer-
ence of MI and show that the functional polymorphisms are not
ssociated with MI in a larger Caucasian case–control sample, sug-
esting that ALOX15 does not play a major role during later stages
f atherosclerosis involving atherothrombotic events.
Such a divergent role of ALOX15 during different stages of
therogenesis would be supported by the temporal and regiospe-
ific expression of ALOX15 and by the expression of its specific
inoleic acid metabolite in the arterial wall. In rabbit atheroscle-
otic lesions, the expression of ALOX15 was 10 times higher in early
esions than in more advanced lesions [23] and the specific ALOX15
etabolite 13(S)-hydro(per)oxy-octadecadienoic acid (13-HpODE)
as abundant in early human atherosclerotic lesions but was not
uring later stages of plaque development [8,9]. In line with this,
recent human genetic study suggested a role for ALOX15 only
uring early atherosclerotic lesion development. This study inves-
igated the association of three ALOX15 promoter polymorphisms
ith carotid plaques and found an association of a certain promoter
aplotype only in the subgroup of the younger stratum, while this
aplotype was not associated with the intermediate phenotype in
he older subgroup [24]. Therefore, it is conceivable that in humans
LOX15 may play an anti-inflammatory role in the initiation of
therosclerosis but to a lesser extend during later stages of athero-
enesis, althoughALOX15expressionduringhumanatherosclerosis
s under debate [1].
There is another possible interpretation of this negative find-
ng. There could be an effect of these rare polymorphisms with
n OR of 1.5 or less, which our study could not detect because
t was underpowered (39%). We had a power of 87% to detect an
ffect of OR=2.0 for a SNP with MAF comparable to c.−292C>T
nd T560M (MAF=1.4%). An indication for a lack of power of the
tudy could be the observed trend for an association of the T560M
olymorphism with MI with a similar risk increase (OR 1.7) as pre-
iously reported for CAD in the CARDIA and the ADVANCE studies
18]. This raises the question why the second functional promoter
olymorphism, c.−292C>T, would not show a similar trend for an
ssociation with MI. This discrepancy may derive from the tissue
pecific influence of the two functional polymorphisms on ALOX15
ctivity. While the T560M polymorphism will result in reduced
LOX15 activity in all cell types [18], the c.−292C>Tpromoter poly-
orphism only leads to increased ALOX15 expression in myeloid
ells [16]. There is indication that endothelial expression of ALOX15
ill result in the formation of arachidonic acid metabolites lead-
ng to vasodilation [25–27], which would only be influenced by the
560M polymorphism and not by the c.−292C>T promoter poly-
orphism. Therefore, the trend of the T560M polymorphism for an
ssociation with MI might indicate that endothelial expression of
LOX15 could be involved during the later atherosclerotic events
eading to MI. On the other side both of these findings could derive
rom chance.
To get additional information on whether this M560 ALOX15
llele is associated with CAD, we investigated its association with
ngiographically documented CAD in a smaller case–control studyrosis 205 (2009) 192–196 195
involving 498 participants [17,28,29]. Again, the T560M polymor-
phism showed a trend to be associated with increased risk for
angiographically defined CAD in this small study (OR 3.30 [CI:
0.68–16.0]; p=0.14) potentially indicating some role as a risk
marker for CAD (data not shown).
The inactivating M560 allele was not linked with a specific
haplotype but was found on four different haplotypes including
the three frequent haplotypes 8, 10 and 14 while being absent on
haplotype 4. These results show that none of the functional poly-
morphisms in ALOX15 do account for the association of haplotype 4
with MI in the MONIKA/KORA case–control study, leaving the pos-
sibility of the presence of another atheroprotectivemutation linked
with this haplotype or of a chance finding.
In summary, we show that the two functional polymorphisms
in ALOX15 are not associated with MI in a large case–control study
which argues that ALOX15 seems less involved during the later
stages of atherosclerosis than eventually during early lesion devel-
opment. Indeed, these activating and inactivating polymorphisms
in theALOX15gene seeminversely associatedwithCADandsuggest
an anti-inflammatory role for ALOX15 during early lesion develop-
ment.
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3 DISCUSSION 
Human ALXR is expressed in almost all leukocytes [90, 93, 94, 224] and is involved in 
inflammatory disease such as rheumatoid arthritis and asthma [165] where it influences cell 
infiltration into tissue. ALXR function is mediated by a variety of pro- and anti-inflammatory 
ligands; all of them are important stimuli of inflammation. However few is known about its own 
transcriptional and translational regulation in monocytes and in macrophages. In this thesis we aim 
at better understand the transcriptional regulation of the ALXR in macrophages and its exact role 
during inflammation. 
 
In this study ALXR expression has been shown to be tightly regulated during monocytes 
differentiation into macrophages. ALXR expression in monocytes is confirmed by previous studies 
in which the ALXR ligand LXA4 was shown to recruit monocytes to the site of inflammation 
without increasing their cytotoxicity and superoxide generations [32, 93]. These monocytes are 
indeed differentiated into pro-resolving M2 macrophages, which take up apoptotic cells from the 
inflamed tissue. Therefore high expression of ALXR in these cells reflects its possible role as an 
anti-inflammatory chemotactic receptor for cells involved in the late phase of inflammation. 
However ALXR expression is almost absent in macrophages. Only increased levels of IFNγ could 
rescue the loss of ALXR transcription during monocytes differentiation into macrophages. Hence 
macrophages might need to be in a stimulatory environment of IFNγ to activate transcription factors 
responsible for ALXR expression. 
IFNγ is an endogenous mediator of immunity and inflammation and plays a complex and central 
role in the resistance of the mammalian host to pathogens. Although originally defined as an agent 
with direct antiviral activity [225], the properties of IFNγ include stimulation of bactericidal activity 
of phagocytes [226], stimulation of antigen presentation through class I and class II major 
histocompatibility complex (MHC) molecules[227], orchestration of leukocyte-endothelium 
interaction [228], effects on cell proliferation and apoptosis [229], activation of macrophages and T 
helper 1 (Th1) cell responses as well as stimulation and repression of a variety of genes [230]. IFNγ 
is a dimerized soluble protein that is secreted by T-lymphocytes and NK cells [230]. Indeed, the 
pro-inflammatory Th1 cells secrete IFNγ [231], which induce the development of classical activated 
M1 macrophages. M1 macrophages display enhanced endocytic functions and have the ability to 
kill intracellular pathogens [232, 233]. Such M1 type-macrophage showed specific M1 markers like 
the T-cells costimulatory proteins CD86 and CD 80 [234]. Since IFNγ has already been shown to 
induce the expression of the mouse homologue of ALXR in microglial cells [235], it may induce in 
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M1 macrophages the expression of ALXR to mediate pro-inflammatory actions. In fact, in 
epithelial cells IFNγ increased the expression of the ALXR specific ligand SAA [236], which is 
increased by as much as 1000 fold in response to acute infection [99] and has been shown to 
provoke a marked increase in the number of PMNs in a mouse air-pouch model [158]. These 
authors have also shown that this effect was abrogated in ALXR-/- mice confirming that SAA binds 
to the ALXR to enhance the recruitment of PMNs into inflamed tissue [158]. In addition SAA has 
been shown to stimulate monocytes via ALXR to produce the pro-inflammatory chemokines CCL2 
[132] and TNFα [237]. Furthermore, in neuroblastoma cell lines, IFNγ in combination with TNFα 
upregulates Aβ42 formation [238], which has a central role in neurotoxicity and has been shown to 
induce chemotaxis of mononuclear phagocytes via ALXR in brain tissue of Alzheimer patients 
[239]. In consequence, IFNγ effect on the expression of ALXR might initiate ALXR to have pro-
inflammatory properties following SAA triggering, such as generation of inflammatory chemokines 
and cytokines and the induction of chemotaxis of pro-inflammatory cells. 
In contrast, treatment with ANXA1 and Ac2-26 of acute inflammation in a mouse model inhibited 
recruitment of PMN, which was markedly attenuated in ALXR-/- mice [158]. Thus, ALXR also 
signals anti-inflammatory effects and inhibits migration of PMNs when pro-resolving mediators are 
present. Indeed, Ac2-26 was also shown to inhibit SAA-induced chemotaxis of macrophages [158] 
and another anti-inflammatory ligand, LXA4, was shown to promote chemotaxis of monocytes 
without leading to cytotoxicity but to nonphlogistic phagocytosis of apoptotic PMNs [32, 33]. 
Hence, upregulation of ALXR in macrophages by IFNγ might also lead to resolution of 
inflammation and tissue repair, when the anti-inflammatory ligands ANXA1, Ac2-26 or LXA4 rise 
in concentration during the resolution phase of inflammation. 
These data support that during inflammation, the ALXR plays a role in chemotaxis of monocytes, 
which results from a gradient of pro-inflammatory or anti-inflammatory ligands. Depending on the 
ligand and the environment of the invaded tissue, the monocyte may then differentiate into either an 
M1 or a M2 macrophage. Since IFNγ is known to induce the differentiation of macrophages into 
pro-inflammatory M1 type macrophages, these results suggest that in the early phase of 
inflammation only M1 macrophages could further be triggered by the pro-inflammatory ligands of 
ALXR to generate inflammatory regulators and to recruit PMN and monocytes that recognize and 
kill pathogen. On the other hand, when anti-inflammatory ligands occur at the site of inflammation, 
these M1 macrophages may re-differentiate into M2 macrophages, and play a role in restoring 
tissue homeostasis. Hence, in monocytes ALXR is probably mediating chemotaxis while in a 
limited set of M1 macrophages first pro- and then eventually anti-inflammatory effects may be 
triggered depending on the local environment.  
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Up to date there are no studies that have characterized the ALXR promoter. In this thesis 
we have defined different 5’UTR of ALXR mRNA in macrophages and found two distinct 
transcriptional start sites separated from each others by 224bp. These mRNAs contain both the 
coding exon (third exon) with one having a longer version of first exon. 5’UTRs play a role in 
translational regulation and conservation of important UTRs between species has been shown 
before [240]. In this line it is notable that part of the long version of the first ALXR exon is 
conserved between mouse, dog, and human, suggesting a possible regulatory role of this region. 
Furthermore it has been estimated that 10-18% of genes express alternative 5’UTRs by using 
multiple promoters [241, 242]. Multiple transcriptional start sites is a result of either a variation in 
the initiation site from one promoter or of the use of separate promoters [243]. To test which 
promoter configuration is present in the ALXR gene, fragments of putative promoter constructs 
were designed upstream of the two transcriptional start sites and tested for their transcriptional 
activity. Constructs were built so that potential downstream elements were included not to miss 
important elements like DNE [244]. From the results obtained, we can conclude that ALXR 
expression is driven by two distinct promoters, P1 and P2. Both promoters lack a TATA boxes at 
position -25 but MatInspector and Alibaba algorithm identified putative basal transcription binding 
sites in promoter P1 and P2. 
P1 contains an OCT1 binding site which has been previously shown to play a critical role in 
preinitiation complex recruitment of promoters that lack TATA boxes. For instance during the 
transcription of the lipoprotein lipase, OCT1 was able to replace the TBP via its interaction with the 
general transcription factor TFIIB [245]. Therefore, such an OCT1-TFIIB preinitiation transcription 
complex may help to recruit the RNA polymerase II and to drive transcription of the ALXR via its 
first promoter P1. Or, like in other cases, OCT1 could act in synergy with recruited transcription 
factors of the same family [246] to upregulate ALXR transcription. Similarly P2 contains the 
putative basal transcription factor binding site for SP1, which is known to bind CpG islands and to 
drive gene transcription of TATA less promoters [247]. Indeed SP1 has two glutamine rich 
transactivator domains A and B, which each interact with the TATA-binding protein TBP and with 
TFIID [248] to recruit the basal transcriptional machinery of RNA polymerase II [249-251]. 
Furthermore, SP1 can either be transactivated via the SP1 binding sites [252] or can be 
superactivated with other DNA-bound SP1 molecules. Further investigation on other putative 
transcription factors upstream of the first promoter and/or on transcription factor protein complexes 
would give us a greater view on the transcriptional machinery recruited to the ALXR promoters and 
its regulation. The existence of two distinct promoters is a sign of different use of gene regulation 
according to environment and stimuli. 
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IFNγ binds to the heterodimeric receptor consisting of the Interferon γ receptor 1 and 2 (IFNGR1 
and IFNGR2) [253] and either activates the JAK/STAT pathway in which STAT proteins 
translocate into the nucleus or induces transcription of Interferon Regulatory Factors (IRF) [254]. 
Both of these pathways enhance gene transcription in response to IFNγ. The first promoter of 
ALXR seems to respond to IFNγ and contains several interferon response elements. Since the 
different constructs of the first promoter are equally stimulated by IFNγ, the shortest version of first 
promoter was investigated for its putative interferon response element. MatInspector revealed that 
IRF4 and IRF7 binding sites were present in the ALXR promoter. Even though mutation in the 
binding site of IRF4 reduced DNA-protein binding and promoter activity, IRF1 was responsible for 
the IFNγ response and not IRF4. All IRFs bind to a consensus sequence A/GNGAAANNGAAACT 
corresponding to the IFN-stimulated response element IRSE [255]. IRF1 is one of the best 
characterized and the highest induced member of the IRF family. For instance, it was shown that 
THP-1 monocytes stimulated with IFNγ resulted in a strong increase in IRF1 binding to the IRSE 
element in the β2-microglobulin promoter [256]. In this study we show that the first ALXR 
promoter P1 contains an IRSE element which is bound by IRF1 when THP-1 macrophages are 
stimulated with IFNγ. The EMSA experiments also indicated that IRF1 is complexed with other 
proteins. Indeed IRF members do not work alone but synergize with other proteins to drive 
regulated transcription of genes [257, 258]. Taken together, these data indicate that the ALXR 
promoter contains an IRSE transcription factor binding site, which is bound by IRF1 to induce 
transcription upon IFNγ stimulation. 
 
However in this study we had some unsolved results concerning the expression of the 
ALXR in macrophages following IFNγ stimulation. Firstly, IFNγ stimulation resulted in a 80-fold 
increase of ALXR mRNA expression but only in a 1.4-fold increase of the luciferase constructs 
with promoter P1. Such different results indicate that the IRSE binding site in the first promoter 
may be not the only transcription factor binding sites that respond to IFNγ. Other genes like IFNβ 
have enhancer elements far upstream of their promoter that increase transcription of their mRNA 
[259]. Accordingly, the ALXR promoter may contain far upstream enhancers that respond to IFNγ 
and that increase ALXR gene transcription eventually in concert with IRF1 binding site. 
Secondly, we were able to detect the ALXR protein in monocytes by FACS analysis and could 
confirm its absence in macrophages. However, we could not detect the ALXR protein by FACS in 
macrophages stimulated with IFNγ. This may be due to technical problems of detaching 
macrophages from cell culture dishes, although we could detect the presence of other cell surface 
receptors on macrophages (data not shown). Western blot analysis could also not solve the question 
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of expression of ALXR on IFNγ stimulated macrophages because no specific antibodies are 
available, although we tried several commercial ones. Corroborating the lack of a specific antibody 
is the observation that no study published a western blot of the ALXR protein so far. 
On the other hand, the lack of ALXR protein in macrophages stimulated with IFNγ may indicate 
that post-transcriptional mechanisms regulate ALXR abundance on the cell surface. INFγ 
stimulated transcription of the ALXR leads presumably to the mRNA containing the longer 5’UTR 
because only the first promoter contains the IRSE element and is responsive to IFNγ stimulation. 
Indeed 5’UTRs were shown to contain regulatory motifs [260, 261] that have an effect on 
translational efficiency. Among the potential regulatory mechanism that could modulate translation 
efficiency are the presence of target sequences for MicroRNAs [262], internal ribosome entry sites 
[263], hairpin secondary structures [264], upstream translation initiation codons (uAUG) and 
upstream open reading frames (uORF). Intriguingly, the longer 5’UTR of the ALXR mRNA 
derived from promoter P1 contains an uORF which may lead to a poor translation of this ALXR 
mRNAs [265]. A recent study revealed that the presence of an uORFs in human genes results in a 
30-80% reduction in protein expression [265-267] or even in a full block of translation. Hence, 
IFNγ stimulation of macrophages may result in ALXR mRNA containing the uORF, which may not 
be efficiently translated and therefore not support membrane expression of the receptor. 
 
Polymorphism in the ALXR gene could alter transcription or lead to amino acid changes 
which could influence progression of inflammation. To investigate whether the ALXR plays a role 
in chronic inflammation, we searched the gene for polymorphisms and investigated the association 
of the polymorphisms with coronary artery disease (CAD), as a model for an inflammatory disease 
(see appendix, supplementary methods). We screened the promoter, the coding region and the 
3’UTR of ALXR from 98 Caucasians for polymorphisms by DHPLC and found 8 mutations. Five 
of these polymorphisms were located in the promoter region, one in the coding region and two in 
the 3’UTR (see appendix, supplementary Table 3). Since 3 mutations (c.-7978 A>G, c.-7986 A>G; 
c.-7893C>T) are located in the first promoter region P1 and mutations in promoters could influence 
transcriptional activity of a gene [268], we tested their effect in reporter assays (see appendix, 
supplementary Figure 1). However none of them altered the transcriptional activity of the first 
promoter P1 in macrophages. Furthermore, no SNPs were observed in the second promoter of the 
ALXR. To investigate whether the ALXR is associated with CAD, we analyzed the association of 
these SNPs in a case-control study involving 238 healthy volunteers and 260 patients with 
angiographically documented CAD [213, 215, 269]. No significant association was observed for 
any of the polymorphisms investigated, although the SNP c.-7978A>G showed a trend for a 
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proatherogenic effect (OR= 1.4; 95%CI; p=0.27) (see appendix, supplementary Table 3). From the 
results obtained, we cannot exclude that there are functional polymorphisms upstream and 
downstream of the regions that were screened. However the absence of functional polymorphisms 
in the regulatory and coding sequences of ALXR suggest that this gene may be important for the 
correct function of cells during chronic inflammation. 
 
In this study, we have described for the fist time the regulatory sequences and the potential 
transcriptional machinery that enhance the expression of the ALXR gene in macrophages. 
Furthermore our data support that in monocytes, ALXR is probably mediating chemotaxis while in 
a limited set of M1 macrophages first pro- and then eventually anti-inflammatory effects may be 
triggered depending on the local environment. Hence this study provides a better insight of the role 
of the ALXR in the inflammatory process and stimulates research in the function of ALXR during 
chronic inflammatory disease 
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4 APPENDIX 
4.1 Supplementary methods 
 
Case-control study 
339 men and 159 women in Zürich volunteered to participate in the study. Written informed 
consent was obtained from all participants and the local ethics committees approved the study. The 
sample consisted of 260 consecutive Caucasian patients with angiographically documented 
coronary artery disease with more than 50% stenosis in at least one coronary artery. The control 
group consisted of 238 Caucasians with no history of CAD, stroke, or peripheral vascular disease 
and was recruited from the general population. Angiographically negative individuals were also 
included in the control group. 81% of the cases and 8% of controls were under cholesterol lowering 
regimen [213, 269]. 
 
Denaturing High-Performance Liquid Chromatography (DHPLC) Analysis 
DNA was extracted from EDTA-supplemented blood samples with the QIamp® DNA Blood Mini 
Kit (Qiagen AG, Hombrechtikon, Switzerland). PCR was carried out in 50μl reaction volumes 
containing 500ng of DNA. The primers (Microsynth, Balgach, Switzerland) used for amplification, 
the size of the amplicons and the respective annealing temperature are listed in the supplementary 
data (supplementary Table 1). The PCR products were denaturated for 2min at 94°C and cooled to 
60°C for reannealing at a temperature ramp rate of 1°C/min. DHPLC was carried out on a WAVE 
DNA fragment analysis system (Transgenomic) [270]. All samples that showed a unique absorption 
pattern were sequenced. 
 
Tetra-primers Analysis 
For each amplification a total volume of 25μl with 150ng of blood DNA, 0.2mM of 
deoxynucleotide triphosphate mixture (dNTPs), 1.5mM of MgCL2 (Solis BioDyne,), 1U of HOT 
FIREPol DNA polymerase (Solis BioDyne,) and titrated amounts of 10 μM of forward and reverse 
primer were used (supplementary Table 2) [271]. PCR reactions were performed under the 
following conditions: a denaturation step for 10min at 95°C followed by the first set of cycles: 
denaturation for 30sec at 95°C, annealing for 30sec at the appropriated annealing temperature and 
extension for 7sec at 72°C. In the allele-specific amplication, DNA was denaturated for 30sec at 
95°C, annealed for 30sec at the appropriated temperature and extended for 7sec at 72°C. A final 
extension for 7 min at 72°C was added and PCR were visualized on a 2% agarose gel. 
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 Statistical analysis 
Association with CAD was analyzed through logistic regression models, using an additive genetic 
model and adjusted for age and sex 
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4.2 Supplementary data 
4.2.1 Supplementary Table 1 
 
 
 
Table 1: Primer sequences for ALXR amplification, PCR conditions and parameters for 
DHPLC analysis 
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4.2.2 Supplementary Table 2 
 
 
Table 2: Primers for Tetra-primer to investigate ALXR promoter mutations 
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4.2.3 Supplementary Table 3  
 
 
 
Table 3: Logistic regression models predicting CAD status for cases. Adjusted for age and sex. 
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4.2.4 Supplementary Figure 1  
 
 
 
Figure 1: P1-414 basal transcription after SNPs site-directed mutagenesis. Luciferase 
expression of the P1-414 promoter with mutations introduced according to the promoter SNPs 
determined (c.-7986 A>G: A-to-G base exchange at position -7986; c.-7978 A>G: A-to-G base 
exchange at position -7978; c.-7893 C>T: C-to-T base exchange at position -7893). Human THP-1 
monocytes were transfected with the constructs, differentiate into macrophages and luciferase 
activity was measured and normalized against the activity of the Renilla luciferase 48hrs later. All 
experiments were done in triplicate and bars indicate the means of three independent experiments 
with three plasmid preparations. Values represent fold induction compared to the P1-414 vector and 
the error bars represent the standard error (± SD). *p<0.05; **p<0.01 
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